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Abstract
Obesity is a serious metabolic disorder that is reaching epidemic
proportions worldwide. One likely reason for this is an increase in energy intake
by certain individuals. This project aimed to examine the role of palatable
feeding-related receptors in the regulation of energy intake, macronutrient
preference and obesity development. This was achieved through an integrative
approach that used dietary intervention, pharmacological manipulation, blood
hormone analysis and receptor binding assays.
The first study of this project aimed to develop a dietary fat-preferring
obese-prone mouse model. The macronutrient preference of five mouse strains
(AKR, A/J, ARC, C57Bl/6 and BALB/c) was examined by placing them on a twochoice high fat and low fat diet protocol for thirty days. It was found that the
C57Bl/6 strain was not only the strongest fat preferrer consuming 72% of their
calories from the high-fat diet, but also the most obesogenic of the inbred
strains.
The next study aimed to determine if drugs that act on palatable feedingrelated receptors can alter the energy intake and macronutrient preference of
the fat-preferring C57Bl/6 mice. Intraperitoneal injection with the CB1 inverse
agonist AM 251, the opioid mu antagonist β-Funaltrexamine and the D2
receptor agonist Bromocriptine similarly reduced total energy intake a specific
reduction of high fat diet intake with no change in low fat diet intake.
The third and final study in this project aimed to examine how the
expressions of the CB1, D2 and opioid mu receptors are altered in the early and
late stages of high fat diet induced obesity. A ligand binding assay was
performed on the cannabinoid CB1 receptor, opioid mu receptor, dopamine D2
Page 6

receptor and dopamine transporter (DAT) of C57Bl/6 mice that were fed a high
fat diet for three and twenty weeks. It was found that central CB1 and D2
receptor binding was increased in reward and feeding-related brain areas
following three weeks of high fat feeding and the CB1 receptor was decreased
following twenty weeks of high fat feeding. Three and twenty weeks of high fat
feeding was found to have no effect on opioid mu receptor binding levels. In
contrast, replacement of the high fat diet at three weeks with a low fat diet for
one and seven days caused an increase in opioid mu receptor binding in the
nucleus accumbens and amygdala but had no effect on CB1, D2 and DAT
binding levels. This raises the possibility that unlike the CB1 receptor, D2
receptor and DAT, the opioid mu receptor is influenced by alterations in short
term energy intake and macronutrient type rather than long term changes in
obesity level. Conversely, the temporal changes in CB1 and D2 receptor
binding that occurred throughout the development of diet-induced obesity may
indicate the important role of these systems in the pathology of this disease.
In conclusion, this study has provided new information regarding the
involvement of palatable feeding-related receptors in macronutrient preference
and obesity development in mice. These findings may assist not only in
understanding the aetiology of obesity but may aid in the design of new
pharmacological treatments for this disease.
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Chapter 1 Review of the Literature
1.1 Obesity, a Modern Epidemic
Obesity is one of the most common and rapidly growing metabolic
disorders in the western world. It has reached epidemic proportions on a global
level with approximately 1.6 billion adults estimated to be overweight and 400
million

obese

(World

Health

Organisation,

2005). The World

Health

Organisation further predicts that in 2015 there will be 2.3 billion overweight and
700 million obese adults worldwide (World Health Organisation, 2005). Obesity
also has enormous social and economic consequences, estimated to cost
Australians $21 billion in 2005 alone (Diabetes Australia, 2006). These alarming
growth rates, coupled with the fact that obesity is associated with type II
Diabetes Mellitus, cardiovascular disease, stroke, dyslipidemias and some
forms of cancer (e.g. endometrial, breast and colon) makes research into the
area of obesity of great importance (Levin and Keesey, 1998, Hill et al., 2000,
Marx, 2003).
The problems of obesity are further compounded by the fact that few
medical treatments exist for this disease. Currently only two pharmacological
medications (sibutramine and orlistat) are approved for weight loss and these
only cause on average 3-5 kg weight loss in obese patients when combined
with diet and exercise (Jain, 2005, Fujioka and Lee, 2007). Another treatment
for obesity is bariatric surgery, however this is not without risks (Poulose et al.,
2005). Therefore, the lack of effective treatments of obesity along with its
prevalence and associated medical complications makes it extremely important
that a clearer understanding of the aetiology of this disease is attained.
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Obesity occurs when an individual’s energy intake exceeds their energy
expenditure (Levin, 2005). It has been shown to develop over an extended
period of time as a result of an interaction between genetic and environmental
factors. Although several genes have been identified as playing an integral role
in the regulation of body weight, the rapid increase in obesity prevalence that
has occurred recently suggests some environmental factors are promoting
excess weight gain (Bloomgarden, 2002, Hill et al., 2003). By determining how
these environmental factors may be modulating energy balance regulation,
measures can be made to create obesity treatments.
One likely environmental culprit causing the current increase in obesity
rates is an increased consumption of palatable, energy dense diets, high in
sugar and saturated fat. The aim of this thesis was to examine the
neurotransmitter systems related to energy intake and palatable feeding in a
rodent model of high fat diet-induced obesity, in which certain mice prefer to
consume a palatable high fat diet.

1.2 High fat Diet-Induced Obesity
As mentioned previously, the increased consumption of energy dense,
high fat “fast food” diets may be one factor promoting the currently elevated
rates of obesity (Hill and Peters, 1998, Boumtje et al., 2005). Several animal
and human studies have been carried out that have shown that a diet high in fat
predisposes certain individuals to obesity (Blundell and Macdiarmid, 1997, Hill
and Peters, 1998, Levin and Keesey, 1998, Hill et al., 2000, Levin and DunnMeynell, 2000, Levin and Dunn-Meynell, 2002). Epidemiological studies on
human populations such as the Leeds high fat study have reliably shown that
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the consumption of high fat diets are positively correlated to weight gain and
obesity (Macdiarmid et al., 1996, Bray and Popkin, 1998). The consumption of
high fat diets in rats has been shown to increase both adipocyte size and
number (Faust et al., 1978). Furthermore, the occurrence of obesity has been
shown to be rare in animals fed a low fat diet (Hill et al., 2000).
Although high fat diets have been implicated in the development of
obesity, the mechanisms by which they do this remain unclear. Some
researchers have suggested that high fat diets may have a lower degree of
satiation. Meal size is reliably greater in rodents fed high fat diets compared to
high carbohydrate diets (Synowski et al., 2005). This effect on feeding also
occurs in humans. Individuals allowed to eat to comfortable fullness reliably
consume a larger amount of energy when they select a range of high fat foods
compared to foods high in carbohydrate or sucrose (Blundell et al., 1994, Green
et al., 1994). This effect of high fat foods has been termed “passive overconsumption” due to the fact that their increased energy density causes the
increase in meal energy intake rather than any increases in feeding (Blundell
and Macdiarmid, 1997).
Other studies have revealed that diets high in saturated fats diminish the
ability of catabolic signals to act on the brain as they reduce blood-brain barrier
transport and interfere with their ability to initiate downstream anorectic
signalling and thus inhibit feeding (Banks et al., 1997, Banks and Farrell, 2003,
Clegg et al., 2003, Banks et al., 2004, Clegg et al., 2005). If diets high in
saturated fats predispose an individual to the development of obesity, then a
logical method for treating obesity may be to decrease one’s motivation to
consume a high fat diet. Reduction of dietary fat by 10% will cause
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approximately 5kg weight loss in obese humans (Astrup et al., 1997).
Furthermore, voluntary feeding has been found to be lower in humans on a low
fat as apposed to a high fat diet (Thomas et al., 1992). Low fat/high
carbohydrate diets have also been shown to have a higher thermic effect and
thus reduction of fat content may slightly increase an individual’s energy
expenditure (Hill et al., 1993).
Previously, a high fat diet-induced obesity model has been produced in
C57Bl/6 mice in our lab (Fig 1.1) (Lin et al., 2000). When given ad libitum
access to a diet that contains 40% fat, 44% carbohydrate and 16% protein,
these mice develop visceral obesity, hyperphagia and hyperglycemia in a
manner similar to humans. Furthermore, it has been previously shown that
these mice become obese in a reproducible series of stages (Lin et al., 2000).
In the early “gaining” stage (1-4 weeks of high fat diet), mice are characterised
by a normal energy intake but elevated body weight and fat gain. Furthermore,
early stage high fat fed C57Bl/6 mice are sensitive to leptin that is administered
both centrally and peripherally. In the middle “defensive” stage (4-15 weeks of
high fat feeding) high fat-fed C57Bl/6 mice become hypophagic, possibly as a
result of levels of anorectic hormones that are increased in order to prevent or
reverse any excess fat gain. Despite this, these mice continue to gain weight,
albeit at a slower rate than in the early stage. Furthermore, these mice are
insensitive to leptin administered peripherally but maintain their sensitivity
centrally. In the late “failure” stage of obesity (15-20 weeks of feeding), these
mice become hyperphagic and their weight gain accelerates. This is possibly
due to these mice becoming insensitive to leptin’s anorectic effects both
centrally and peripherally.
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Figure 1.1. Body weight (A) and energy intake (B) of male C57Bl/6 mice fed
either a low fat or high fat diet for 19 weeks. Figure adapted from (Lin et al.,
2000).
Whilst previous work on this model has examined the relationship
between the hypothalamus and obesity, little work has been carried out on
palatable feeding-related pathways. The relationship of palatable feedingrelated receptors with energy intake, palatable feeding and obesity development
will be discussed below.
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1.3 Obesity and Reward
Whilst previous research on obesity has focused on homeostatic feeding,
little research has been performed on non-homeostatic or palatable feeding.
Previous work has shown obese individuals preferentially consume foods higher
in fat (Castonguay et al., 1984, Greenberg and Weatherford, 1990, Drewnowski
et al., 1992). It is possible that the increased preferential fat consumption seen
in obese humans and rodents may be due to alterations in palatable feeding
systems of the brain. Indeed one study has revealed a positive correlation
between an individual’s sensitivity to reward and their preference for fatty foods
(Davis et al., 2007).
The relationship between obesity and food reward remains controversial.
Some have argued that obese individuals suffer from “reward deficiency
syndrome” which drives their overeating, whilst others have argued that
heightened reward sensitivity may be a causal factor for obesity (Davis et al.,
2007). One study has found that obese individuals have enhanced sensitivity in
brain areas associated with the sensory processing of food (Wang et al., 2002).
This inconsistency in the literature may be explained by a previous study by
Davis and Fox which revealed that a non-linear relationship exists between food
reward and BMI in humans (Davis and Fox, 2008). Humans in the normal to
overweight range of BMI (i.e. 18-30) have a positive relationship between
reward sensitivity and body weight, whilst those with moderate to extreme
obesity (i.e. >30) have an inverse relationship (Davis and Fox, 2008).
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1.4 Macronutrient Preference and Diet-Induced Obesity
Previous studies have revealed a link between obesity and macronutrient
preference in both humans and rodents (Greenberg and Weatherford, 1990,
Drewnowski et al., 1992). It. has been found that obese men and women
commonly have a higher preference for foods that have a higher nutrient source
from fat as opposed to carbohydrate (Drewnowski et al., 1992). Also, obese
women report a higher intake of fat and their relative weight is correlated with
their total fat and saturated fat intake (Romieu et al., 1988). Other researchers
have found the fat preference of an individual is directly correlated with their
body fat percentage (Mela and Sacchetti, 1991). Furthermore, in a study of
weight-discordant monozygotic twins, obese twins reported a higher preference
for dietary fat than their lean siblings (Rissanen et al., 2002).
Rodent studies have also revealed a link between preferential fat
consumption and obesity development. In rodents, preferential fat intake has
been shown to increase the adiposity of Sprague Dawley rats, despite an equal
caloric consumption of carbohydrate preferring controls (Smith et al., 1998).
Furthermore, obese Zucker rats show an increased preference for fatty foods in
dietary selection studies compared to lean controls (Castonguay et al., 1984,
Greenberg and Weatherford, 1990). Similarly, obese ob/ob mice prefer to
consume a higher proportion of fat as apposed to carbohydrate compared to
lean controls (Romsos and Ferguson, 1982). One study revealed that obese
prone rats not only have an increased preferential fat consumption compared to
obese resistant rats, but their level of fat preference was also positively
correlated with their body weight gain and was negatively correlated with an
anorectic drug’s ability to reduce fat intake (Chandler et al., 2005).

Page 21

There is evidence that macronutrient preferences for fats are partially
heritable (Reed et al., 1997). Indeed studies have shown that there are several
neurotransmitters that are not only involved in the control of food intake, but are
also involved in the control of macronutrient preference. These signals include
leptin, galanin, the melanocortins, dopamine, cannabinoids and opioids and will
be discussed below.

1.5 Leptin, Obesity and Macronutrient Preference
One major signal that has been shown to have strong control over
feeding and satiety is leptin. Leptin is a 16 kDa hormonal peptide that is
produced mainly by white adipose tissue (Zhang et al., 1994). Mutations that
result in a lack of leptin production result in massive levels of obesity in both
rodents and humans (Montague et al., 1997, Friedman and Halaas, 1998).
Furthermore, the central and peripheral administration of leptin has been shown
to reduce both energy intake and body weight in both rodents and primates
(Friedman and Halaas, 1998, Tang-Christensen et al., 1999). Leptin gene
expression has been shown to be decreased in response to food restriction,
and increased following feeding (Saladin et al., 1995).
Whilst it is well established that leptin is a strong regulator of feeding
behaviour, most human obesity cases are not attributable to defects in this
molecule or its receptor (Montague et al., 1997). In fact, the majority of obese
humans have been shown to have elevated levels of leptin in conjunction with a
decrease in leptin’s effectiveness following administration (Lonnqvist et al.,
1995, Heymsfield et al., 1999). This raises the likelihood that obese individuals
are leptin insensitive.

Page 22

The existence of leptin insensitivity has been confirmed in rodents. In
one study by Lin et al, C57Bl/6 mice were shown to become progressively
insensitive to leptin’s effects as they became obese (Lin et al., 2000). Mice were
found to be sensitive to the anorectic effects of peripherally administered leptin
after one week of high fat feeding. After eight weeks of feeding the mice were
found to be insensitive to peripherally administered leptin but were sensitive to
leptin that was injected directly into the cerebral ventricles. Finally, after
nineteen weeks of high fat feeding, C57Bl/6 mice were obese and were
insensitive to both peripherally and centrally administered leptin (Lin et al.,
2000). These findings reveal a progressive breakdown of the mechanisms that
regulate energy balance as high fat diet-induced obesity develops.
Leptin’s main site of central activity has been shown to be in the
hypothalamus. Leptin receptors have been discovered in a variety of
hypothalamic sites such as the arcuate nucleus (ARC), ventromedial nucleus
(VMN),

dorsomedial nucleus (DMN), lateral hypothalamus (LH) and

paraventricular nucleus (PVN) (Mercer et al., 1996). Further studies have
revealed the presence of leptin and insulin receptors on DA neurons in the VTA
and substantia nigra (Figlewicz et al., 2003). These anatomical studies have
revealed the potential of adiposity signals to act not only on satiety circuits in
the hypothalamus but also to act directly on reward-related circuitry (Fig 1.2).
Whilst leptin has long been associated with the regulation of energy
balance, its control over feeding has been thought to be mainly due to metabolic
and satiation effects in the hypothalamus rather than the regulation of reward
and palatability. Recent studies have begun to show that this is not the case.
Chronic food restriction and maintenance of a low body weight have been
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shown to augment the rewarding effects of a variety of drugs of abuse (Carr,
2002). Furthermore, it has long been known that periods of fasting can enhance
the reinforcing properties of drugs of abuse (causing relapse) and the central
administration of leptin can reverse this phenomenon (Figlewicz, 2003).

Mesolimbic
dopamine
pathway

Nucleus
accumbens

VTA
Dopamine

-

D2/D1R

Hypothalamus
MC4R

-

-

AgRP/
NPY

VMH/PVN

+

POMC/
CART

+

Arcuate Nucleus
Leptin
Increased
fat mass

Decreased energy intake/
Decreased palatable food intake/
Increased energy expenditure

Figure 1.2. Effects of increased plasma leptin on hypothalamic and mesolimbic
related energy balance. Abbreviations: Agouti-related peptide (AgRP), Cocaine
and Amphetamine related transcript (CART), Dopamine receptor 1 and receptor
2 (D1/D2R) Melanocortin receptor 4 (MC4R), Paraventricular nucleus (PVN),
Ventromedial hypothalamus (VMH), Ventral tegmental area (VTA).

Further studies have been carried out to evaluate the rewarding
properties of leptin. One popular method used to determine the rewarding
properties of food and drugs is through the use of a conditioned place
preference (CPP) paradigm (Figlewicz et al., 2004). In this task, palatable food
is consistently administered to a food-restricted rodent in a “place” (i.e. a
visually distinctive patterned box) in order to condition them to prefer being in
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that “place” (Figlewicz et al., 2004). Studies by Figlewicz et al found that the
central administration of leptin or insulin prevents the formation of a CPP in rats
that were fed a rewarding high fat diet or sucrose (Figlewicz et al., 2001,
Figlewicz et al., 2004). It should be noted that the doses of leptin and insulin
administered during this task were subthreshold and thus were too low to cause
a decrease in food intake or weight loss (Figlewicz et al., 2004).

1.6 Hypothalamic Control of Feeding and Macronutrient Preference
There are several different types of orexigenic and anorexigenic
neuropeptidergic neurons in the hypothalamus that have their activity regulated
by leptin. These include Neuropeptide Y (NPY), Agouti-related Protein (AgRP),
melanin

concentrating

stimulating

hormone

hormone
(α-MSH),

(MCH),

galanin,

neurotensin

(NT),

orexin,

α-melanocyte

corticotropin-releasing

hormone (CRH), and cocaine- and amphetamine-regulated transcript (CART)
(Sahu, 2003). Of all these neuropeptides, three will be discussed below,
including α-melanocyte stimulating hormone (α-MSH), Agouti-related Protein
(AgRP) and galanin. These three neuropeptides have been chosen due to the
fact that they have been implicated not only in the control of energy intake, but
also of fat preference (Koegler et al., 1999, Odorizzi et al., 2002, Samama et al.,
2003).
Two signals that are involved in feeding and energy balance, alphamelanocyte stimulating hormone (α-MSH) and agouti-related peptide (AgRP),
are members of the melanocortin family. The melanocortin family consists of an
agonist (α-MSH, which is derived from the larger protein proopiomelanocortin,
POMC) and an antagonist (AgRP), which both act on central melanocortin
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receptors (Hillebrand et al., 2006). The melanocortin receptor family consists of
five receptors; however the effects on energy balance are mediated centrally by
MC3 and MC4 receptors (Hillebrand et al., 2006). Leptin acts in the arcuate
nucleus of the hypothalamus to increase the activity of POMC/α-MSH neurons
and decrease the activity of AgRP neurons, thus resulting in a decrease of
energy intake and an increase in expenditure (Fig 1.2) (Hillebrand et al., 2006).
As well as controlling energy intake, melanocortins have been found to
exert some control over the preferential consumption of palatable high fat diets
(Samama et al., 2003). In a study by Samama et al., C57Bl/6J mice were
treated with the MC4R agonist MTII whilst given ad libitum access to a three
choice diet paradigm; a palatable high fat diet, a high carbohydrate diet, and a
protein diet (Samama et al., 2003). It was found that fat consumption was
selectively reduced by 70% following a low dose (0.1mg/kg) of MTII (Samama
et al., 2003). No reductions in carbohydrate or protein occurred (Samama et al.,
2003). The selective reduction of fat intake in this experiment may be explained
by the possibility that MTII may decrease the rewarding value of dietary fat
(Samama et al., 2003). Another study has also revealed that the ability of MTII
to reduce fat intake is negatively correlated with an individual’s fat preference
and their level of obesity (Chandler et al., 2005).
Studies on mutant mouse models have also revealed a link between the
melanocortin system and preferential fat consumption. Lethal yellow agouti
(Ay/a) mice over express the melanocortin antagonist agouti and as a result,
they prefer to consume more fat than carbohydrate compared to their wildtype
littermates (Koegler et al., 1999).
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The endogenous melanocortin MC4 receptor antagonist AgRP has also
been shown to be involved in macronutrient selection (Hagan et al., 2001). In a
study by Hagan et al., the reward-related opioid system was shown to be
involved in AgRP’s short-term but not long-term effects on feeding (Hagan et
al., 2001). As it is known that opioids not only influence feeding but also have
an effect on food preference, they tested if centrally administered AgRP would
alter macronutrient selection. Following administration, it was found that AgRP
selectively enhanced the intake of a high fat, but not a low fat diet. This
selective increase in fat intake may be explained by the fact that the opioid
mediated effects of AgRP may increase the rewarding value of dietary fat.
Another neuropeptide shown to be involved in the control of feeding
behaviour is Galanin. Galanin is a hypothalamic 29-amino acid peptide that has
been shown to increase feeding behaviour (Leibowitz, 2005). It is expressed in
several hypothalamic areas including the paraventricular nucleus, the
perifornical lateral hypothalamus and the arcuate nucleus (Leibowitz and
Wortley, 2004).These neurons have been shown to extend throughout the
hypothalamus where they act upon two galanin receptor subtypes; GALR1 and
GALR2 (Gundlach et al., 2001). In obesity, galanin has been shown to be
increased in the plasma of both obese rats and humans (Baranowska et al.,
1997, Pedrazzi et al., 1998). This raises the likelihood that this orexigenic
feeding signal may be involved in the pathogenesis of obesity.
As well as stimulating energy intake, galanin may also be involved in
macronutrient preference. Galanin’s relationship with macronutrient preference
is revealed through examination of the Brattleboro rat (Odorizzi et al., 2002).
The Brattleboro rat is unable to produce arginine-vasopressin due to a single
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base deletion in its genetic code (Odorizzi et al., 2002). As galanin is
coexpressed with arginine-vasopressin, the Brattleboro mutation leads to an
over expression of galanin mRNA due to negative feedback stimulation
(Odorizzi et al., 2002). Brattleboro rats have been shown to have elevated
levels of galanin in the hypothalamic paraventricular nucleus and also consume
60% more fat than their wild-type counterparts, the Long Evans rat (Odorizzi et
al., 2002). Furthermore the central administration of two Galanin antagonists,
C7 and galantide, to the PVN caused a significant decrease in the Brattleboro
rat’s preferential fat consumption (Odorizzi et al., 2002).
Galanin’s relationship with preferential fat consumption has also been
seen in galanin knockout (GKO) mice. When presented with only a high fat diet,
GKO mice consume less than their wildtype littermates. Furthermore, when
given the choice, wildtype mice preferentially consume three times more fat
than GKO mice. Also, chronic administration of galanin to GKO mice partially
reverses their fat avoiding phenotype (Adams et al., 2008).
Whilst a relationship between galanin and fat preference is seen in the
galanin-overexpressing Brattleboro rat, it is not as apparent in wild type rats.
One experiment has revealed that the central administration of galanin to the
paraventricular nucleus does not specifically increase fat preference, however it
does increase the consumption of a rat’s preferred diet (Kyrkouli et al.).
Furthermore, it has been shown that the central injection of galanin to the
hypothalamic paraventricular nucleus of Sprague-Dawley rats has no effects on
preferential fat consumption (Smith et al., 1997). Despite this, Galanin activity
has been shown to be most strongly activated by blood triglyceride levels
(Leibowitz, 2005). Consumption of fat, but not carbohydrate or protein causes
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an increase in hypothalamic galanin gene expression, peptide production and
peptide release by as much as 40% (Leibowitz et al., 1998). This supports the
existence of a non-homeostatic, positive feedback loop between galanin and
dietary fat, which may contribute to the hyperphagia that is usually associated
with the consumption of foods high in saturated fats (Leibowitz, 2005).
In summary, POMC, AgRP and galanin are three hypothalamic signals
that have been implicated in the control of both feeding and macronutrient
preference. Three other systems that have been shown to be involved in
macronutrient preference and palatable feeding are the dopaminergic system,
the opioid mu receptor and the cannabinoid CB1 receptor.

1.7 Dopamine, Feeding and Obesity
Dopamine is a catecholamine neurotransmitter found abundantly
throughout the mammalian brain (Pijl, 2003). It’s actions are mediated by at
least five G-coupled protein receptors that are classed as either D1-like (D1 and
D5) or D2-like (D2, D3 and D4) (Pijl, 2003). D1-like receptors modulate cellular
activity by stimulating the formation cAMP, whilst D2-like receptors are inhibitory
Gi-coupled receptors that inhibit cAMP accumulation (Jackson and WestlindDanielsson, 1994, Jaber et al., 1997).
Dopamine has been shown to regulate palatable feeding via the
mesolimbic (rewarding) circuit of the brain (Hajnal et al., 2004). Consumption of
palatable foods and drugs of addiction activate dopamine releasing neurons
that project from the ventral tegmental area (VTA) to the nucleus accumbens
and ventral striatum (Spanagel and Weiss, 1999, Huang et al., 2005).
Microdialysis studies have shown that dopamine release is increased in the
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nucleus accumbens of rats fed a highly palatable diet (Martel and Fantino,
1996). Furthermore, this dopamine release in the nucleus accumbens has been
shown to be positively related to the amount of palatable food ingested
(Schneider and Koch, 2005).
Dopamine’s involvement with feeding is further highlighted through the
production of dopamine deficient mutant mice. Inactivation of the tyrosine
hydroxylase gene generates mice that cannot produce dopamine and as a
result are hypoactive, have reduced preference for sucrose and a palatable diet,
and are hypophagic to the extent that they usually die of starvation by four
weeks of age (Szczypka et al., 2001). However, the selective restoration of
dopamine to the caudate putamen has been shown to restore the feeding
behaviour of these mice (Szczypka et al., 2001). Other research however, has
revealed that sucrose preference is maintained in dopamine deficient mice
(Cannon and Bseikri, 2004).
Further pharmacological studies have revealed that the administration of
the dopamine reuptake inhibitor GBR 12909 to rats causes an increase in
responding rates for food rewards (Kelley and Lang, 1989). Also, administration
of d-amphetamine, a potent dopamine releasing drug, has been shown to
enhance feeding and the preference for sugar (Evans and Vaccarino, 1987).
This suggests elevations in brain dopamine may enhance the palatability of
food.
Other research has revealed conflicting results for dopamine and feeding
behaviour. Administration of methylphenidate, a dopamine transporter inhibitor,
to obese humans has been shown to reduce energy intake and preferential fat
intake, likely through an increase in brain dopamine (Goldfield et al., 2007).
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Conversely,

decreasing brain

dopamine via

some antipsychotics (i.e.

olanzapine and clozapine) has been shown to result in overeating and weight
gain (Baptista, 1999). This raises the possibility that obese individuals have low
levels of brain dopamine. One study has found obese-prone rats have
decreased levels of extracellular dopamine in the nucleus accumbens
compared to obese resistant rats (Geiger et al., 2008). Other studies have also
revealed central dopamine levels are decreased in multiple rodent models of
obesity (Geiger et al., 2007). And yet no studies have determined whether this
weight-gain associated decrease in dopamine is a cause of, or a reaction to, the
development of obesity.
The disparate findings for dopamine and feeding may be explained by
the varied sites and feeding pathways that dopamine is involved in. Whilst
increases in dopamine in the mesolimbic pathway cause an increase in
palatable feeding, an increase in the hypothalamus causes a decrease in
feeding (Yang et al., 1997). Studies have shown that direct administration of
amphetamine into the lateral hypothalamus causes a decrease in feeding in rats
via an increase in synaptic dopamine release (Leibowitz, 1975a, Leibowitz,
1975b).
The strength of changes in central dopamine may also explain the
conflicting results seen in feeding studies. Studies have found that dopamine
increases and decreases during feeding in the striatum in a transient and
regulated manner (Sotak et al., 2005). It has been suggested that either
flooding striatal synapses with dopamine via amphetamine, or drastically
reducing dopamine via a lesion can mask this important regulated phasic
release of dopamine and thus disrupt normal feeding (Sotak et al., 2005).
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One of the receptors that dopamine acts on is the D2 receptor. D2
receptors exist both postsynaptically and as presynaptic autoreceptors (Pijl,
2003). Activation of these autoreceptors has been shown to reduce
dopaminergic activity. The administration of quinpirole, a D2/D3 agonist, has
been shown to inhibit cell firing on neurons in the substantia nigra by acting on
presynaptic autoreceptors. This consequently causes a decrease in dopamine
release in the nucleus accumbens and thus a decreased preference for
palatable foods (Cooper and Al-Naser, 2006). Conversely, D2 levels can also
be regulated directly by synaptic dopamine. Production of hyperdopaminergic
mutant mice has been shown to cause a downregulation of D2 mRNA levels in
the striatum (Fauchey et al., 2000).
The dopamine D2 receptor has three different allelic variants (A1/A1,
A1/A2, and A2/A2) (Epstein and Leddy, 2006). The A1 allelic variant has been
associated with reduced dopamine activity, fewer receptors and obesity (Noble
et al., 1994). Furthermore, the A1 variant has also been associated with
addictive behaviours such as alcoholism and cigarette smoking and a reduced
sensation of dopamine stimulated reward (Noble et al., 1994, Blum et al., 1996).
Human subjects who carry at least one A1 allele are high in food reinforcement
and have an elevated energy intake compared to controls without an A1 allele
(Epstein et al., 2004, Epstein et al., 2007). This has lead to the hypothesis that
obese subjects suffer from “reward deficiency syndrome”. As a result of their
inefficient dopaminergic system, obese individuals are driven towards
behaviours like palatable food ingestion that increase central dopamine levels
back to normal (Epstein and Leddy, 2006). However, another study has
revealed that obese subjects carrying an A1 allele have greater reward
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sensitivity than normal-weight controls (Davis et al., 2008). The researchers
suggest that this may be explained by the A1 allele interacting with another
gene to produce enhanced dopaminergic activity.
The “reward deficiency syndrome” hypothesis has been further
established through functional magnetic resonance imaging studies on obese
humans. Binding of [14C] raclopride, a specific D2 receptor antagonist, has been
shown to be reduced in the striatum of obese humans subjects in a manner that
is proportional to their BMI (Wang et al., 2001). This has led to the proposal that
the low D2 receptor levels in obese humans may drive pathological eating as a
means of compensation for their under stimulation of dopamine related reward
and motivation circuits (Wang et al., 2001). However, work by Davis et al. has
led to a conflicting explanation of these findings (Davis et al., 2004). These
researchers have found that overweight human subjects are initially more
sensitive to reward than their lean counterparts. It is only once subjects became
chronically obese that their sensitivity to reward decreases compared to
overweight subjects. This finding has led these researchers to propose that the
reduced striatal D2 levels seen in chronically obese humans are more likely a
consequence of their overeating and not the cause. Constant stimulation of D2
receptors through palatable feeding may lead to a defensive downregulation of
their levels.
Different feeding and energy states have been shown to affect dopamine
D2 receptor activity. Food restriction in rats causes an increase in quinpirole
induced (D2 agonist) Fos immunostaining in the globus pallidus and ventral
pallidum (Carr et al., 2003). Furthermore, quinpirole-stimulated [35S] guanosine
triphosphate-γS binding in the CPu is also increased in food restricted rats. This
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suggests the increased Fos staining in food restricted rats is due to an increase
in functional coupling between D2 receptors and its Gi subunit (Carr et al.,
2003).
A study by Huang et al. has revealed that obese mice fed a palatable
high fat diet have higher levels of D2 receptor mRNA expression in the ventral
caudate putamen compared to lean low fat controls (Huang et al., 2005). The
researchers in this study suggested the elevated levels of D2 gene expression
in this area may be the result of a compensatory response to a decreased
activation of the D2 receptor pathway induced by the high food intake of the
obese mice (Huang et al., 2005). However, studies that have examined D2
protein binding levels have found that they are decreased in the striatum of
obese mice, rats and humans (Wang et al., 2001, Huang et al., 2006, Hajnal et
al., 2008).
Dopamine activity is also affected by the dopamine transporter (DAT).
The dopamine transporter regulates synaptic dopamine concentration by the
reuptake of the neurotransmitter back into presynaptic terminals. Disruption of
the DAT gene leads to an increase in synaptic dopamine along with an elevated
energy intake and preference for palatable foods (Pecina et al., 2003).
Conversely, inhibition of the dopamine producing enzyme tyrosine hydroxylase
with α-methyl-p-tyrosine, can decrease synaptic dopamine and in turn cause a
downregulation of DAT production. This downregulation is compensatory and
acts to return synaptic dopamine levels back to baseline.
Like the D2 receptor, there are a three common allelic variants for the
dopamine transporter; 9/9, 9/10 and 10/10 (Epstein and Leddy, 2006). The
10/10 variant is associated with increased dopamine transporter levels and thus
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lower levels of synaptic dopamine (Heinz et al., 2000). In humans, the 10/10
allele has been associated with obesity in African American but not Caucasian
smokers (Epstein et al., 2002).
The genetic elimination of DAT production in mice has helped to further
elucidate dopamine’s role in feeding. Using “knockdown” techniques in mice, a
mutant strain was developed with only 10% of normal DAT production (Pecina
et al., 2003). This led to synaptic dopamine levels that were 70% higher than
the wild type controls (Pecina et al., 2003). These mice were found to have
higher food and water consumption (Pecina et al., 2003). Interestingly, these
mice worked harder for sweet rewards but showed the same amount of
orofacial “liking” expressions as their wild type counterparts. This finding
suggests that dopamine is involved in the incentive salience (wanting) of a
natural reward but not the hedonic impact (liking) (Pecina et al., 2003).
Differing states of energy balance have also caused variations in DAT
expression and activity. Studies have revealed that food deprivation decreases
the activity and mRNA expression of DAT in rats (Patterson et al., 1998). It has
also been shown that DAT mRNA expression is increased by direct
intracerebroventricular infusion of insulin (Patterson et al., 1998). Furthermore,
DAT mRNA has been shown to be increased in obese leptin insensitive Zucker
(fa/fa) rats (Figlewicz et al., 1998). These findings reveal a defensive
mechanism whereby synaptic dopamine levels are decreased in states of
positive energy balance by increased DAT levels and increased in negative
energy balance by reduced DAT levels. This serves to drive energy intake
levels back to normal.
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The above findings strongly implicate dopamine in feeding. Furthermore,
the implication of the dopaminergic system in palatable feeding makes it an
attractive candidate to investigate in terms of its relationship to fat preference
and obesity.

1.8 Cannabinoids, Feeding and Obesity
Another neurotransmitter family that has been shown to be involved in
both feeding and palatable feeding is the endocannabinoids (Gardner, 2005).
The endocannabinoid system is represented by distinct receptors (CB1, CB2,)
along with a variety of endogenous ligands. The CB1 receptor was first cloned
in 1990 and was determined to be a G-coupled protein that inhibits adenylate
cyclase activity in a dose dependant manner (Matsuda et al., 1990). It is found
abundantly in areas of the brain including mesolimbic and meso-forebrain
structures (Wilson and Nicoll, 2002). The CB2 receptor was cloned later in 1993
and was thought found to be predominantly expressed in peripheral tissue
(Cota et al., 2006). Recent work has revealed that the CB1 receptor is also
expressed peripherally and the CB2 receptor is found centrally (Cota et al.,
2006, Gong et al., 2006).
Following

the

discovery

of

the

cannabinoid

receptors,

several

endogenous ligands have also been identified. The first endocannabinoid
identified was anandamide (N-arachidonoyl-ethanolamine, AEA) (Devane et al.,
1992). Anandamide is a partial agonist at CB1 receptors and a weak CB2
agonist (Devane et al., 1992, Hillard et al., 1999). Anandamide is expressed in
several areas of the brain with the highest levels seen in the brainstem,
hippocampus and striatum (Bisogno et al., 1999). Following the discovery of
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anandamide was 2-arachidonoyl-glycerol (2-AG) (Mechoulam et al., 1995). 2AG shares a similar pattern of expression in the brain to anandamide (Bisogno
et al., 1999). However, unlike anandamide, 2-AG has much more potent
agonism of the CB1 and CB2 receptors and is considered to be the most
effective endocannabinoid that has been discovered (Sugiura et al., 1999,
Sugiura et al., 2000). More recently discovered endocannabinoids are noladin
ether, virodhamine and N-arachidonoyldopamine (Cota et al., 2006).
It has long been known that the stimulation of CB1 receptors by
marijuana (and it’s active ingredient Δ9 –tetrahydrocannabinol, Δ9 –THC)
causes an increased appetite in humans (Abel, 1975). In one study, the acute
administration of Δ9 –THC to humans was shown to increase the consumption
of chocolate milkshakes along with the appreciation of their palatability
(Hollister, 1971). Other studies using marijuana cigarettes on humans have
revealed an increase in the consumption of sweet snack foods, such as
cookies, cakes and candy bars (Foltin et al., 1986, Foltin et al., 1988).
Studies on rodents have also revealed a link between cannabinoids and
feeding. In one study, the administration of Δ9 –THC (0.5–2.0 mg/kg, orally.)
and the endogenous cannabinoid anandamide (1.0–10.0 mg/kg, s.c.) to presatiated rats was found to reduce the latency to initiate feeding in an open field,
cause small increases in energy intake, increase the duration of eating and
increase the total number of eating bouts (Williams and Kirkham, 2002). In
another experiment, the administration of Δ9 –THC (0.5–3.0 mg/kg, i.p.) and
anandamide (0.5–3.0 mg/kg, i.p.) to rats caused an increase in the total number
and duration of licks of a palatable sucrose solution (Higgs et al., 2003).
Furthermore, the administration of the CB1 antagonist SR141716 was found to
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significantly reduce the number of sucrose solution licks in these rats (Higgs et
al., 2003). The central administration of 2-AG to the shell of the nucleus
accumbens, a key brain area involved in reward, causes a potent and dosedependant increase in feeding (Kirkham et al., 2002). Furthermore this increase
in feeding is reversed by administration of the CB1 antagonist SR141716
(Kirkham et al., 2002).
Like CB1 agonists, CB1 antagonists also have an effect on feeding. The
administration of the CB1 antagonist SR141716 to rodents has also been
shown to cause a decreased preference for rewards such as ethanol and
sucrose (Arnone et al., 1997). Furthermore, the oral administration of
SR141716 has been shown to reduce daily energy intake and body weight in
diet-induced obese mice (Ravinet Trillou et al., 2003).
The production of CB1 receptor knockout mice has further highlighted
this receptor’s involvement in feeding and reward. CB1 receptor knockout mice
have been shown to have a dramatically reduced voluntary consumption of
alcohol and palatable sucrose solutions (Hungund et al., 2003, Poncelet et al.,
2003).

Furthermore,

dopamine

release

in

the

reward-related

nucleus

accumbens has been shown to be reduced in CB1 receptor knockout mice
following alcohol consumption (Hungund et al., 2003). Morphine induced
dopamine release in the nucleus accumbens has also been shown to be
reduced in CB1 receptor knockout mice, along with a reduced morphine self
administration (Mascia et al., 1999, Cossu et al., 2001).
In regards to feeding and energy balance, CB1 receptor knockout mice
show a resistance to the development of obesity when placed on an obesogenic
diet compared to wild-type littermates (Ravinet Trillou et al., 2004).
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Furthermore, when CB1 receptor knockout mice are placed on a two-choice
high fat/low fat they show a delayed response to the palatable high fat diet, but
their high fat preference is maintained (Ravinet Trillou et al., 2004). This raises
the possibility that the CB1 receptor is not involved in fat preference. However,
it is possible that this maintenance of high fat preference is due to
compensation by other systems involved in energy intake and fat preference.
Different states of feeding and energy balance have been shown to alter
CB1 receptor levels. Harrold et al. has revealed that CB1 receptor density is
decreased in the hippocampus, cortex, nucleus accumbens and entopeduncular
nucleus of palatable diet-fed obese rats (Harrold et al., 2002). The researchers
of this study have suggested that the down-regulation of CB1 receptors in these
reward-related areas is likely to be the result of increased activation from the
consumption of a palatable obesogenic diet (Harrold et al., 2002).
Previous studies have revealed that obesity can lead to alterations in
endocannabinoid levels both peripherally and centrally (Matias and Di Marzo,
2007). The endocannabinoid system has been described by researchers as
being tonically overactive both peripherally and centrally in obesity and
hyperglycemia (Matias and Di Marzo, 2007). This is evidenced by the fact that a
higher efficacy of CB1 antagonists is seen in obese as compared to lean
rodents (Chambers et al., 2004). Furthermore, obese rodents do not need to be
deprived of food in order for CB1 antagonists to be effective, unlike their lean
counterparts (Di Marzo and Matias, 2005). Endocannabinoid levels have also
been reported to be higher in the hypothalamus of leptin deficient ob/ob mice
and

Zucker

rats

(Di

Marzo

et

al.,
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2001).

Furthermore,

levels

of

endocannabinoids have also been found to be increased in the visceral fat and
plasma of obese humans (Bluher et al., 2006).
The

above

findings

reveal

a

strong

relationship

between

endocannabinoids, the CB1 receptor and palatable feeding. For this reason, the
expression of the CB1 receptor will be worth examining in a model of obesity
and macronutrient preference.

1.9 Opioids, Feeding and Obesity
Opioids have also been implicated in the control of palatable feeding.
Endogenous opioids bind to three types of G-coupled protein receptors: the mu
opioid receptor, the delta opioid receptor and the kappa opioid receptor.
Investigations into the physiological roles of these receptors have revealed that
they have differing roles in specific opioid activities (Cota et al., 2006). Whilst all
opioid receptors have been shown to have some involvement in feeding, the
opioid mu receptor has been shown to be the strongest regulator of the
rewarding aspects of feeding (Cota et al., 2006).
Opioid mu receptors are widely expressed in several areas of the brain
including the striatum, amygdala, and thalamus (Mansour et al., 1987). They
are acted upon by a variety of endogenous opioid ligands such as β-Endorphin,
Met-enkephalin and Leu-enkephalin, endomorphin-1, endomorphin-2, βneoendorphin and dermorphin (Hadcock and Scott, 2005, Cota et al., 2006).
Pharmacological stimulation of opioid mu receptors by morphine has
been shown to preferentially increase the consumption of palatable diets
(Gosnell et al., 1990, Levine et al., 1995). Also, central administration of the
opioid mu receptor specific agonist D-Ala2,Nme-Phe4,Glyol5-enkephalin
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(DAMGO) causes a distinct increase in energy intake and preferentially
enhances the consumption of palatable high fat foods (Zhang et al., 1998,
Zhang and Kelley, 2000). Furthermore, this DAMGO induced fat preference is
completely abolished by the peripheral administration of the opioid antagonist
naltrexone (Zhang et al., 1998). It should also be noted that central infusion of
DAMGO into the reward-related nucleus accumbens causes a preferential
increase in the consumption of palatable, non-caloric saccharin solutions in
water deprived rats (Zhang and Kelley, 2002). This suggests that the opioid mu
receptor may mediate its actions by increasing the reward value of palatable
food irrespective of its caloric content.
The use of opioid mu specific antagonists has further revealed an
involvement of this receptor in feeding and palatable feeding. Ventricular
administration of the opioid mu specific antagonist β-Funaltrexamine causes a
decrease in food deprivation-induced hyperphagia (Arjune et al., 1990).
Furthermore, the administration of β-Funaltrexamine has been shown to also
reduce the consumption of palatable diets high in fat or sucrose (Islam and
Bodnar, 1990, Beczkowska et al., 1992).
Whilst pharmacological studies have revealed a clear link between
opioids and enhanced palatable feeding, work on mutant mouse models has
revealed conflicting data. One study found that mutant mice lacking either βendorphin or enkephalin have a reduced responding for palatable food
reinforcers (Hayward et al., 2002). However, other research has revealed an
inverse relationship between β-endorphin and feeding. Male mice that were
engineered to lack β-endorphin production were found to be hyperphagic and
obese (Appleyard et al., 2003). The researchers suggest that whilst β-endorphin
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is involved in palatable feeding, the overall effect of the removal of ß-endorphin
under ad libitum access to food appears to be an increase in food intake,
despite a reduction in the reward value of food (Appleyard et al., 2003). Thus
beta-endorphin may have a dual role in both promoting palatable feeding and
reducing appetitive feeding (Appleyard et al., 2003).
The endogenous opioid mu receptor ligand enkephalin has also been
implicated in feeding. Research by Kelly et al. has revealed that long term
restricted consumption of a highly palatable chocolate Ensure® (Abbott
Nutrition, Columbus, OH, USA) diet in rats leads to a decrease in
preproenkephalin gene expression in the nucleus accumbens despite no
changes in body weight (Kelley et al., 2003). Furthermore, acute food
deprivation has been shown to cause an increase in preproenkephalin mRNA
expression regardless of long-term energy balance (Kelley et al., 2005). The
researchers of these studies suggest the increases and decreases in
preproenkephalin mRNA occur as compensation to decreased and increased
levels of striatal enkephalin respectively (Kelley et al., 2003, Will et al., 2007).
These findings suggest preproenkephalin activity is positively related to shortterm energy intake and palatability.
The use of opioid mu receptor knockout mice has further implicated this
receptor in the control of palatable feeding. Studies have shown that CXBX
mice, which are deficient in the opioid mu receptor, have a decreased
preference for saccharin solutions compared to wild-type controls (Yirmiya et
al., 1988). However, other research involving opioid mu knockout mice has
raised the possibility that this receptor may not be as heavily involved in energy
intake as previously thought. Research groups have shown that opioid mu null
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mice have normal levels of energy intake when placed on lab chow or a
palatable high fat diet (Tabarin et al., 2005). However this lack of hypophagia
may be reflective of compensation by the redundant neural systems that control
energy intake, or of compensatory neural changes that may have occurred
throughout the lives of the opioid mu receptor null mice.
Another study on mu receptor deficient mice has found that its
involvement in energy balance regulation depends both on diet and sex. A
study by Zuberi et al has revealed that male, and to a lesser extent, female
opioid mu knockout mice, have increased adiposity when fed a normal diet as a
result of an increased energy intake. In contrast, opioid mu receptor KO mice
showed decreased levels of food intake and obesity on a sweet-high fat diet
(Zuberi et al., 2008). Thus the palatability or sweetness of a diet may be a factor
that influences the opioid mu receptor’s control over energy balance.
Due to the fact that compensatory neural mechanisms may disguise the
role of the opioid mu receptor in mu opioid receptor deleted mice, the
“knockdown” approach has been used to characterise it’s involvement in
feeding. The knockdown technique involves the temporary elimination of the
expression of a gene by administration of an anti-sense oligodeoxynucleotide.
This eliminates the possibility of any compensatory neural changes occurring
during the life of an affected rodent. Knockdown of exons 1, 2, 3 and 4 of the
opioid mu receptor gene has been shown to reduce body weight, food intake
and water intake in rats (Leventhal et al., 1996).
Different feeding and physiological conditions have been shown to affect
the mu opioid receptor and endogenous opioid levels. One experiment revealed
the chronic consumption of a high fat diet for 12 weeks leads to an increase in
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hypothalamic mu opioid receptors (Barnes et al., 2003). Other research has
revealed that the chronic exposure of rats to a palatable diet for 17 weeks leads
to an increase in opioid mu receptor binding in forebrain areas including the
fundus striati, dorsal endopiriform nucleus, medial preoptic area, basolateral
amygdala and basomedial amygdala (Smith et al., 2002). The researchers
explained these results by suggesting that the release of endogenous opioids
may have been inhibited by some regulatory signal involved in feeding (i.e.
leptin or insulin) (Smith et al., 2002). This reduction of endogenous opioids may
in turn have caused a compensatory upregulation of the opioid mu receptor.
Obese prone rats (Osborne-Mendel) have been shown to have increased
opioid mu receptor protein and mRNA expression in the hypothalamic arcuate
nucleus compared to obese resistant rats (S5B/Pl) when both are fed lab chow
(Barnes et al., 2006). Furthermore, low doses of the opioid mu agonist DAMGO
[d-Ala2-N-Me-Phe4-Glycol5]-enkephalin to Osborne-Mendel rats was found to
increase energy intake and preferential high fat diet intake. However,
administration of the same dose to S5B/Pl rats did not increase energy intake
but did increase fat preference. Barnes et al. suggest that the elevated
hypothalamic opioid mu receptor levels in Osborne-Mendel rats may contribute
to their susceptibility to obesity as well as their preference for diets high in fat.
The above findings reveal a strong link between endogenous opioids, the
opioid mu receptor, palatable feeding and obesity. For this reason, future
studies should examine the opioid mu receptor in a model of obesity and
macronutrient preference.
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Table 1.1. Summary of receptors and signals related to feeding, macronutrient
preference and obesity
Effects of agonist/antagonist
Changes during obesity
administration on food intake
and macronutrient preference
Dopamine
Decreased (humans) (Wang et -agonist: decreased preference
D2 receptor
al., 2001)
for high fat/ high sugar diet
Decreased (obese fa/fa rats)
(Cooper and Al-Naser, 2006)
(Hamdi et al., 1992)
Decreased (late-stage obese
C57Bl/6 mice) (Huang et al.,
2006)
Dopamine
Decreased (late-stage obese
-DAT inhibitor: decreased food
Transporter
mice) (Huang et al., 2006)
intake/fat intake in humans
(Goldfield et al., 2007)
Opioid
Mu Increased (rats) (Smith et al.,
-Antagonist: decreased food
receptor
2002)
intake (Cole et al., 1997)
-Agonist: fat preference
enhanced (Zhang et al., 1998)
Cannabinoid Decreased (rats) (Harrold et
Antagonist: decreased food
CB1 receptor al., 2002)
intake (Ravinet Trillou et al.,
2003)
Galanin
Increased (rats) (Pedrazzi et
-Increased food intake (Kyrkouli
al., 1998)
et al., 1990)
Increased (humans)
-increased preferred diet
(Baranowska et al., 1997)
(Kyrkouli et al., 2006)
Leptin
Increased (humans) (Lonnqvist -Decreased food intake (Mistry
et al., 1995)
et al., 1997)
Increased (late-stage obese
-Decreased fat preference
mice)(Lin and Huang, 1999)
(Wetzler et al., 2005)
α-MSH
Decreased (POMC mRNA,
-Decreased food intake (Kask
late-stage obese mice) (Huang et al., 2000)
et al., 2003)
-Decreased fat preference
(MC4R agonist) (Samama et
al., 2003)
AgRP
Increased (rats) (Dunbar et al., -Increased food intake (Tang2005)
Christensen et al., 2004)
-Increased fat preference
(Tracy et al., 2008)
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1.10 Summary:
In summary, obesity is a rapidly growing disease characterised by
excessive weight gain whereby energy intake exceeds energy expenditure.
Obesity is caused by an interaction of an individual’s genetics with their
environment (energy intake and energy expenditure). The current project will
only focus on energy intake as it is hypothesised that the increased
consumption of energy dense palatable foods may be one causative factor for
the current obesity epidemic. Indeed, when rodents are given ad libitum access
to a high fat diet they reliably become obese.
Currently one means of treating obesity is to place individuals on low
fat/low calorie diets. Whilst low fat/low calorie diets have been shown to cause
weight loss in obese individuals, compliance on such diets is low. Furthermore,
obese individuals that discontinue a low fat diet and return to their previous
eating habits undergo rebound weight gain back to their previous weight. A
treatment that increases an obese patient’s compliance on a low fat diet may be
an effective means of aiding in the treatment of obesity. By reducing an
individual’s motivation to consume diets high in fat and consequently energy, it
may be possible to slow, stop or even reverse the current worldwide obesity
epidemic.
Currently a wealth of research is being carried out on the central
mechanisms that control satiety and hunger. The influences of Leptin and other
hypothalamic signals such as α-MSH, AgRP, NPY and CART on feeding and
obesity are well established. Leptin inhibits feeding by stimulating anorectic
peptides such as α-MSH and inhibits orexigenic peptides such as AgRP (Table
1.1). Conversely, the relationship between the development of high fat diet-
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induced obesity and palatable feeding-related receptors is less clear. This
project will examine the dopaminergic, opioid and cannabinoid systems in a fatpreferring obese-prone mouse model.

Previous work has shown that the

stimulation of these three systems promotes palatable feeding (Table 1.1).
However, a clear understanding of the relationship these systems have with the
aetiology of obesity remains to be determined.

1.11 Aims and Objectives
This project aims to study the role of the dopamine D2, cannabinoid CB1
and opioid mu receptors in macronutrient preference and the development of
high fat diet-induced obesity. This includes selecting an appropriate animal
model, followed by pharmacological and dietary interventions to determine the
relationship of the D2, CB1 and mu receptors to macronutrient preference,
energy intake and diet-induced obesity. Finally, temporal and site-specific brain
changes in these receptor systems will be examined in the high fat-preferring
obese-prone mouse model.

1.11.1 Comparison of the fat preference of a previously established obese
mouse model to a variety of other mouse strains.
Previous studies have shown that obese individuals self-report an
increased consumption of palatable, energy dense foods that are high in fat
(Drewnowski et al., 1992). This raises the possibility that obese-prone
individuals may be driven to consume these palatable energy dense diets.
Previously, an obese-prone model in C57Bl/6 mice has been established in our
lab. This project aims to examine the macronutrient preference of C57Bl/6 mice
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and compare it a variety of other inbred strains. It is hypothesised that the
underlying genetic background that makes C57Bl/6 mice susceptible to the
development of obesity may also drive them to preferentially consume an
energy dense high fat diet. By establishing an animal model that explores the
causes of dietary saturated fat preference, the underlying mechanisms for the
development obesity and macronutrient preference may be determined and
thus a valid obesity treatment may be discovered

1.11.2 Confirm the involvement of palatable feeding-related receptors in fat
preference and energy intake via pharmacological manipulation
Upon development of this animal model this study will examine the role
of the palatable feeding-related systems in both fat preference and energy
intake via pharmacological methods. This experiment aims to use a
cannabinoid CB1 receptor antagonist, opioid mu receptor antagonist, and a
dopamine D2 receptor agonist to attempt to alter the fat preference and energy
intake of the obese-prone C57Bl/6 mice. As these receptors have been
implicated in both appetitive and palatable feeding, it is hypothesised that the
selected drugs will alter both the total energy intake and fat preference of these
mice (Table 1.1).

1.11.3 Examine palatable feeding-related receptors in the fat-preferring mouse
model in the early and late stages of high fat diet-induced obesity
Previously, our lab has shown that C57Bl/6 mice reliably become obese
in a reproducible series of stages when fed a high fat diet (Lin et al., 2000).
Initially, the high fat and low fat fed mice consume similar amounts of food.
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However, after three weeks the energy intake of the high fat fed mice begins to
decrease compared to the low fat controls possibly as a result of a central
defence against their weight gain. By twenty weeks of high fat feeding, C57Bl/6
mice become hyperphagic and gain weight at an accelerated rate which may be
indicative of a breakdown in the central defence against weight gain. Thus it
appears that three weeks of high fat feeding is associated with an initiation of a
defensive period whilst twenty weeks of feeding is associated with a failure in
this defence. As a result, the role of the dopamine, cannabinoid CB1 and opioid
mu receptors will be analysed at these two stages of high fat diet-induced
obesity in C57Bl/6 mice. This shall be done via ligand receptor binding assay. It
is hypothesised that the levels of the CB1 receptor, opioid mu receptor and
dopamine D2 receptor will be differently altered in the early and late stages of
diet-induced obesity as a result of the disparate levels of central energy balance
regulation.
Previous studies that have examined dopaminergic, cannabinoid or
opioid receptors in obesity have done so by measuring them at only one time
point. This makes it hard to determine whether any changes that have occurred
are a cause or consequence of the development of obesity. By analysing these
receptors at both a pre-obese and post-obese stage this project will provide a
clearer understanding of the relationship these receptors have to the
development of high fat diet-induced obesity.

1.12 Hypotheses
The main hypothesis of this study is that individuals that are genetically
predisposed to the development of obesity are also predisposed to develop a
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preference to consume obesogenic diets. This preference to consume energy
dense palatable foods may be one of the factors that drive the development of
obesity. Furthermore, it is hypothesised that the palatable feeding-related CB1,
opioid mu and dopamine D2 receptors are importantly involved in the regulation
and control of this fat preference and obesity development in obese-prone
individuals.
Previous studies have shown that C57Bl/6 mice are predisposed to the
development of obesity when fed a high fat diet. In this study it is hypothesised
that these mice will also be predisposed to the development of a preference to
consume an energy dense high fat diet over a low fat diet. It is also
hypothesised that the genetic predisposition of the C57Bl/6 mice to fat
preference can be modulated by affecting the activity of the reward-related
opioid mu, cannabinoid CB1 and dopamine D2 receptors. Inhibition of the CB1
and opioid mu receptors and stimulation of the D2 receptor will decrease the
consumption of an obesogenic high fat diet.
Finally it is hypothesised that the expression of the opioid mu,
cannabinoid CB1 and dopamine D2 receptors will be altered in both the early
and later stages of obesity development. These alterations will highlight the
importance of palatable feeding-related receptors in the development of obesity.
In the earlier stages it is expected alterations in these receptors may reflect a
defensive response against the overconsumption of the high fat diet. Whilst in
the later hyperphagic stage of obesity it is expected that the expression of these
receptors will be altered in a way that reflects a loss of regulation of palatable
feeding.
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Chapter 2: Comparison of the fat preference of a previously
established obese mouse model to a variety of other mouse
strains

2.1 Introduction
Previously an obese-prone model in C57Bl/6 mice has been established
in our lab. This project aims to examine the macronutrient preference of
C57Bl/6 mice and compare it to a variety of other inbred strains. It is
hypothesised that the underlying genetic background that makes C57Bl/6 mice
susceptible to the development of obesity may also drive them to preferentially
consume an energy dense high fat diet. If environmental conditions are kept
consistent between strains, the genetic influences involved in the control of fat
preference may be determined. The aim of this experiment is to examine the
macronutrient preferences of a variety of strains of mice, which will help in the
development of an appropriate animal model for the analysis of fat preference.

2.2 Materials and Methods
2.2.1 Animals
All mice were housed individually in an environmentally controlled room
◦

(22 C, 06:00-18:00 light, and 18:00-06:00 dark). All mice were given ad libitum
access to water and food throughout each experiment. Mice were first fed
standard laboratory chow for the first week in order to acclimatize them to their
new surroundings. Fifty, eight-week old male mice were obtained from the
Animal Resources Centre (Perth, Western Australia): C57Bl/6J, ARC, A/J, AKR,
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and BALB/c (n = 10 for each strain). All mice were placed on a two-choice diet
paradigm for thirty days (low fat- normal protein diet and high fat-normal protein
diet; Table 2.1). The two-choice diet was given to the mice by simply placing the
separate diets in distinct sections of the cage’s feeder. Macronutrient intakes
were determined during the experiment by weighing 48-hour intakes of both
diets along with the exclusion of any spillage. Body weight was determined
every two days throughout the thirty-day study. Following thirty days of diet
exposure, all mice were euthanized via an intraperitoneal injection of sodium
pentobarbitone (120mg/kg). All mice were killed between the hours of 08000900 so as to avoid any circadian variations. Following euthanasia, the carcass
was dissected and the liver and fat pads (epididymal, subcutaneous,
interscapular and perirenal (epididymal + perirenal = visceral fat)) were
removed and weighed. Tibial length was also measured to evaluate the body
size of each individual mouse.

2.2.2 Serum Leptin Radioimmunoassay
Mice were sacrificed and their blood was collected via right ventricle
puncture. The blood samples were centrifuged at 4000rpm for ten minutes. The
plasma was then carefully removed from the packed hematocrit and stored at 20ºC. Serum leptin was then determined by using a Linco RIA kit for Rat leptin
(Linco Research, Inc. USA).
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Table 2.1. Composition of the high fat and low fat diets
used throughout the entire study
High fat diet Low fat diet
Total energy, kcal/100g
Fat
40
Protein
16
Carbohydrate
44
Protein, g/kg
Casein
Gelatine
Carbohydrates, g/kg
Cornflour
Sucrose
Fat, g/kg
Copha
Beef Lard
Sunflower oil
Fatty
Acid
Composition, % fat.
Saturated
Monounsaturated
n-6 PUFA*
Energy density

16
16
74

125
50

91
50

432
60

624
60

80
80
41

0
0
41

60
25
15
3.80 kcal/g

13
21
66
2.59 kcal/g

Foods were made from semisynthetic material according
to the recommendation of “AIN93 Diet for Laboratory
Rodents (Reeves PG, 1993)”. *: PUFA: polyunsaturated
fat

2.2.3 In Situ hybridisation Analysis of POMC and AgRP and Galanin
Upon sacrifice, brains were removed from the mice and then immediately
frozen on crushed dry ice. The brain tissue was then sectioned coronally using
a cryostat (14µm) at –18ºC. Sections were thaw-mounted onto baked slides
pre-treated with silane (8 sections / slide). Brain sections were immediately
fixed in ice-cold 4% phosphate-buffered paraformaldehyde. Acetylation was
carried out in 0.25% acetic anhydride in 0.1M triethanolamine buffer (pH 8.0).
Sections were then dehydrated in ethanol and stored at -70ºC until use.
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The antisense oligoprobes used were; POMC: 5’- CGT TCT TGA TGA
TGG CGT TCT TGA AGA GCG TCA CCA GGG GCG TCT-3’ (J00612, 547591), and AgRP: 5’-TGC AGC AGA ACT TCT TCT GCT CGG TCT GCA GTT
GTC TTC TTG AGG-3’ (MMU89486, 411-455) and 5’-TGC TTG CGG CAG
TAG CAA AAG GCA TTG AAG AAG CGG CAG TAG CAC-3’ (MMU89486,
763-806), and Galanin: 5’-GAG AAA ATC CAT TCT AGT GCG GAC ATT GTT
GCT CTC AGG CAG GGG-3’ (NM010253.3, 387-431). All oligoprobes were
labelled with a 10-fold molar excess of [35S] dATP (specific activity: 1000
Ci/mmol,

Amersham,

Buckinghamshire,

UK)

and

terminal

transferase

(Promega, Madison, WI), and purified over a Microspin G-50 column
(Amersham). The probe concentration was 107 pcm of [35S] labelled probes in
750 µl of hybridisation solution the probe specificities for POMC, Galanin and
AgRP were tested prior to this experiment.
The hybridisation was carried out by incubating the sections in
hybridisation buffer (50% deionised formamide, 4 X SSC, 10% dextran
sulphate, 1 X Denhardt’s solution, 0.2% sheared salmon sperm DNA, 0.1%
long-chain polyadenylic acid, 0.012% heparin, 20mM sodium phosphate, pH
7.0, 106/75µl of labelled probe and 5% DTT) at 37ºC for 16 hours. After
hybridisation, labelled sections were washed in 1 X SSC buffer at 55ºC three
times for 20 minutes each followed by two 1-hr incubations in 1 X SSC at room
temperature.

The

sections

were

then

opposed

to

Hyper-β-max

film

(Amersham).
After exposure for the appropriate amount of time (3-4 weeks), the level
of mRNA levels portrayed on the autoradiographs were quantitatively analysed
by using a computer assisted analysis system connected to a GS-690
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densitometer (Multi Analyst, BIO-RAD, USA). Expression levels of mRNA were
obtained by measuring the average density of each region in five adjacent brain
sections, and then the values were compared against a

14

C-labelled

autoradiographic standard (Amersham, USA). Following exposure to X-ray film,
all slides were stained with Cresyl violet to allow the identification of specific
neuroanatomical structures with a mouse atlas (Paxinos G, 2002). Data was
analysed using the SPSS statistical package (SPSS inc., Chicago, IL) via 1-way
ANOVA and significant phenotype differences were then ascertained with posthoc Tukey-Kramer-HSD tests for multiple comparisons.

2.3 RESULTS
2.3.1 Energy intake and diet preference
The patterns of diet choice for each strain over the thirty-day feeding
period can be observed in figures 2.1 and 2.2. Following the thirty-day period it
was found that three of the strains of mice were high fat diet preferrers
(C57Bl/6, p < 0.05, AKR, p < 0.05, and ARC, p < 0.05), whilst the A/J and
BALB/c mice had no preference for either diet (consuming 58% and 53%
respectively of the high fat diet, Fig. 2.3). The C57Bl/6 mice were found to have
the highest preference for fat consuming 72% of their calories from the high fat
diet (Fig. 2.3). Both the C57Bl/6 and ARC mice were found to have significantly
consumed a greater percentage of the high fat diet when compared to the
BALB/c mice via an independent t-test (consuming 18.9% and 12.7 % more
energy from fat respectively, p < 0.05). The total energy consumption and
consumption of both diets for all strains can be seen in figure 2.2. Analysis of
figure 2.2 reveals that the C57Bl/6 mice ate 56% more of the high fat diet than
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the BALB/c mice (p < 0.05). The ARC mice were found to have eaten
significantly more of the high fat diet than all strains of mice except for the
C57Bl/6 mice. The BALB/c and ARC mice were found to have significantly
consumed 46% and 54% more of the low fat diet than the C57Bl/6 mice
respectively (p < 0.05). Analysis of the total calories consumed over the thirtyday period revealed that the ARC mice ingested more calories than all strains of
mice (p < 0.05). Both the C57Bl/6 and AKR mice were found to have consumed
15% and 14% more calories than the BALB/c mice respectively (p < 0.05).

2.3.2 Body weight gain and fat depots
Due to the fact that the mice from each strain were dissimilar in size, a
graph of body weight gain divided by initial body weight was produced (Fig.
2.4). This graph allows a more accurate comparison of the increases in body
weight between the different strains of mice as it takes into account the different
sizes of each mouse before the initiation of the diet. Analysis of this graph
reveals that the C57Bl/6 mice clearly gained the most weight over the thirty-day
feeding period. The C57Bl/6 mice had a significantly greater BWG/IBW than the
A/J, ARC and BALB/c mice for the entire thirty-day feeding period (p < 0.05).
The BWG/IBW of the C57Bl/6 mice did not however become significantly
greater than the AKR mice until twenty days of feeding had passed (p < 0.05).
Although the C57Bl/6 mice had the highest BWG/IBW over the thirty-day
period, it was found that the ARC mice had the highest adiposity index (total
dissected fat / initial body weight; Table 2.2). The C57Bl/6J mice were found to
have an adiposity index that was only higher than that of the BALB/c mice
(20%, p < 0.05). The ARC mice however, had an adiposity index that was
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significantly greater than the AKR, A/J and BALB/c mice by 31%, 74% and 54%
respectively (p < 0.05).

2.3.3 Correlation analysis of energy intake and body weight
Statistical analysis of the relationship between total energy intake and
final body weight revealed positive correlations in two of the fat-preferring
strains: C57Bl/6 (R = 0.806, p < 0.005) and AKR (R = 0.646, p < 0.044, Fig.
2.5). Also, a positive correlation was revealed between total energy intake and
body weight gain (adjusted by initial body weight) for the C57Bl/6 strain (R =
0.679, p < 0.031). No relationship between body weight and high fat diet intake
was revealed for any of the strains. However, a positive correlation was
revealed for all strains between total energy intake and total high fat diet intake
(R = 0.802, p < 0.001). No relationship between total energy intake and total low
fat diet intake was revealed for any of the strains.
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Figure 2.1. Food intake of five mouse strains self-selecting from two diets (high
fat and low fat) for a period of thirty days. A: C57Bl/6, B: AKR, C: A/J, D: ARC,
E: BALB/c. Food intake was measured every 48hrs. A’: C57BL/6, B’: AKR, C’:
A/J, D’: ARC, E’: BALB/c. Total energy intake for the low fat and high fat diets
following thirty days of feeding. ×: p ≤ 0.05, high fat vs. low fat.
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Figure 2.2 Average total energy intake of both diets for each mouse strain after
the thirty day feeding period. a: vs. BALB/c, p ≤ 0.05, b: vs. C57Bl/6, p ≤ 0.05, c:
vs. all strains, p ≤ 0.05.

a

a

Figure 2.3. Percentage of total energy intake from high fat diet intake consumed
over the thirty-day feeding period. a: vs. BALB/c, p ≤ 0.05.
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Table 2.2. Fat deposits, liver weight and tibial length
following the thirty-day high fat/low fat feeding period
C57Bl/6 AKR
A/J
Initial Body Weight (g)
22.06a
25.68b 22.02a
Final Body Weight (g)
27.86a
30.42b 25.27c
Body Weight Gain (g)
5.8a
4.74a,b 3.24b
0.678a, b
0.267a
0.509a
0.194a
1.658a

Epididymal Fat (g)
Perirenal Fat (g)
Subcutaneous Fat (g)
Interscapular Fat (g)
Total body fat (g)

0.805 a
0.25a,d
0.351b
0.186a
1.596a

0.530b,d
0.158b
0.471a
0.184a
1.343a,c

of each mouse strain
ARC
35.16c
41.42d
6.26a

BALB/c
20.4d
23.75c
3.35b

1.359c
0.561c
0.789c
0.369b
3.078b

0.521d
0.191b,d
0.326b
0.177a
1.189c

Liver (g)
1.262a
1.293a 0.944b 2.186c 1.237a
a
Tibial Length (mm)
18.33
19.50b 18.72a 21.2c 17.33d
a,b
Total Dissected Fat / 0.042
0.041a,c 0.031a,c 0.054b 0.035c
Initial Body Weight
Data not sharing the same superfixes are significantly different via independent
t-test (p ≤ 0.05).

a
b
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0.3
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Figure 2.4. Body weight gain expressed as a fraction of initial body weight over
the thirty-day feeding period. a: C57Bl/6 vs. ARC, A/J, BALB/c, p ≤ 0.05, b:
C57Bl/6 vs. AKR, p ≤ 0.05.
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Figure 2.5. Correlations, A. AKR: total energy intake vs. final body weight. B.
C57Bl/6: total energy intake vs. final body weight. C. C57Bl/6: total energy
intake vs. body weight gain / initial body weight. D. All strains: total energy
intake vs. total high fat diet intake.

2.3.4 Plasma leptin levels, hypothalamic arcuate POMC and AgRP mRNA and
paraventricular Galanin mRNA expression in C57Bl/6 and BALB/c mice
Upon completion of the thirty-day feeding period the C57Bl/6 strain was
determined to have the highest preference for the high fat diet whilst the BALB/c
strain was found to have no preference for either diet. Plasma leptin levels were
determined for these two strains only, as their phenotypes were deemed most
appropriate for comparison in a fat preference model. Radioimmunological
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assay of their blood plasma revealed that the C57Bl/6 mice had a level of blood
plasma leptin that was 82 % greater than the BALB/c mice (C57Bl/6: 2.32 ±
0.31 ng/ml, BALB/c: 1.27 ± 0.14 ng/ml, p < 0.05). When plasma leptin was
expressed as a fraction of their total fat, no significant differences were found
between the two strains (C57Bl/6: 1.27 ± 0.23 ng/ml, BALB/c: 1.01 ± 0.08 ng/ml,
p = 0.33).
Levels of gene expression of POMC, AgRP and Galanin were also
determined for the two strains via in situ hybridisation. Expression of both
POMC and AgRP genes was localised in the arcuate nucleus of the
hypothalamus, whilst Galanin was found in the hypothalamic paraventricular
nucleus. Upon quantification, it was found that there were no significant
differences in the expression of POMC mRNA between the two strains of mice
(C57Bl/6: 223.98 ± 15.5 nCi/g tissue, BALB/c: 202.96 ± 27.88 nCi/g tissue, Fig.
2.6 A). Conversely, quantification of AgRP expression revealed that the BALB/c
mice had a level that was 33.7% higher than the C57Bl/6 mice (C57Bl/6: 169.85
± 20.05 nCi/g tissue, BALB/c: 227.04 ± 6.83 nCi/g tissue, p < 0.05, Fig. 2.6 B).
Quantification of Galanin mRNA expression revealed that the C57Bl/6 mice had
a level that was 118.3% greater than the BALB/c mice (C57Bl/6: 779.9 ± 57.0
nCi/g tissue, BALB/c: 357.3 ± 24.6 nCi/g tissue, p < 0.05, Fig. 2.6 C).
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Figure 2.6. Levels of hypothalamic arcuate nucleus AgRP and POMC and
paraventricular Galanin mRNA expression of C57BL/6 and BALB/c mice
following thirty-days of two-choice high fat and low fat feeding. *: p ≤ 0.05.

2.4 Discussion
This experiment revealed that two inbred strains (AKR and C57Bl/6) and
one outbred strain (ARC) of mice were fat preferrers. Of these strains the
C57Bl/6 mice were found to be the strongest fat preferrers. The C57Bl/6 mice
were also found to be the most obesogenic of the inbred strains having the
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highest BWG/IBW and energy efficiency for the thirty days. This finding is in
agreement with previous studies showing that this strain of mouse will reliably
become obese when placed on a high fat diet (Surwit et al., 1997, Lin et al.,
2000, Surwit et al., 2001). The reliable weight gain that these mice produce on a
high fat diet coupled with their high fat preference makes the C57Bl/6 strain an
excellent candidate for use in an animal model that examines fat preference
and its relationship with obesity.
As revealed in table 2, the ARC mice were much heavier than all the
other strains at the beginning of the experiment. Analysis of the tibial length of
the ARC mice revealed that these mice were much larger than the other strains
and thus the elevated energy intake and fat pad mass observed for these mice
may be a result of their increased size. The high adiposity index and fat
preference seen in the ARC strain does make these mice an attractive option
for use in a fat preference mouse model. Also, the large size of these mice
would improve the ease with which blood and tissues could be removed for
biological analysis. However, it is in the opinion of these researchers that the
disproportionate size of these mice compared to the other smaller strains would
make the comparison of energy intake and body weight changes difficult and
inaccurate. This consequently, makes them an unviable option for use in a
mouse model.
This experiment also revealed that the A/J and BALB/c inbred mouse
strains developed no preference for either diet. Although no significant
differences were found for adiposity index, percentage fat consumption or
BWG/IBW between the two groups of mice it is likely that the BALB/c mice will
be more appropriate for use in an animal model as a control group for the

Page 64

analysis of fat preference. Whilst there were no significant differences in the
percentage of high fat diet consumption between the two groups, trends
revealed the BALB/c mice consumed slightly less fat. Also the standard
deviation for the percentage fat consumption of the A/J was noticeably high (i.e.
greater than thirty percent of the mean). This suggests that these mice had
difficulty adapting to the two-choice diet paradigm and as a result the data for
their energy intake may not be indicative of their actual macronutrient
preference. In an experiment by Smith et al. it was similarly found that the A/J
strain was unable to adapt to a three-choice diet paradigm (Smith et al., 2000).
Whilst the cause of this inadequacy in the A/J mice is uncertain, their inability to
adapt to the two-choice diet makes them an unviable option for use in an animal
model.
This experiment was carried out on the premise that the consumption of
a high fat diet will reliably produce obesity. Interestingly, statistical analysis
revealed no correlation between either the percentage of fat consumption (i.e.
fat preference) or total fat consumption and BWG/IBW across all strains.
However, in accordance with other research, a positive correlation was revealed
between total fat consumption and total energy intake across all strains
(Warwick, 2003). Also, no correlation was revealed between total carbohydrate
consumption and total energy intake. In a study by Covasa et al., rats that were
adapted to a high fat diet were found to have a reduced sensitivity to the
satiating effect of intestinal oleic acid (Covasa and Ritter, 1999). This finding
suggests diets high in saturated fat cause a reduction in the ability of fat to
further inhibit energy intake (Covasa and Ritter, 1999).
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In this study, it was found that the C57Bl/6 mice had a positive
correlation between total energy intake and body weight gain (adjusted for initial
body weight). This finding is concordant with the logical premise that a calorie is
a calorie regardless of macronutrient source (Buchholz and Schoeller, 2004).
However, as previous studies have shown that energy dense saturated fats are
more potent in their ability to cause weight gain than diets low in fat and high in
carbohydrate, it is possible that the feeding period in this experiment was too
short and thus the obesogenic effects of a diet high in saturated fat were not
revealed (Boozer et al., 1995, Wang et al., 1998, Lin et al., 2000, Petro et al.,
2004). Regardless, it is surprising that no correlations were found between fat
intake and body weight gain or adiposity. Therefore, whilst fat intake may not
directly cause obesity, the chronic consumption of saturated fats may cause a
gradual breakdown in the regulation of energy intake which may in turn cause it
to increase. Thus it seems fat preference may indirectly cause obesity as it is
this increase in total energy intake (regardless of macronutrient type) that
subsequently causes weight gain.
This experiment has confirmed that a noticeable amount of variation
occurs in the macronutrient preference of different strains of mice. As all mice in
this study were obtained from the same commercial supplier, their
environmental conditions prior to the initiation of this experiment were kept
considerably constant between all strains. Also, the environmental conditions
for all mice remained consistent throughout the duration of this experiment, and
as a result, it can be proposed that this variation in macronutrient preference
may be due to genetic influences. This premise is in accordance with several
studies showing the existence of strong neurophysiological influences that can
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affect an individual’s motivation to consume different macronutrients (Glass et
al., 1999). Pharmacological studies on rats and mice have revealed several key
neuroanatomical sites and neurotransmitters that influence macronutrient
preference (Glass et al., 1997, Zhang et al., 1998, Fulton et al., 2000, Odorizzi
et al., 2002, Horvath, 2003, Small et al., 2003).
The central administration of several neuroreceptor agonists and
antagonists has been shown to exert controlling effects over the consumption of
different macronutrients. Administration of Dopamine D2, Cannabinoid CB1,
Opioid mu receptor agonists have all been shown to preferably cause increases
in the consumption of dietary fat possibly due to the fact that they cause
increased activity in a part of the brain involved in reward, the shell of the
nucleus accumbens (Glass et al., 1997, Fulton et al., 2000, Odorizzi et al.,
2002, Cooper and Al-Naser). Also the administration of Galanin has been
shown to increase fat preference whilst NPY has been shown to preferably
increase carbohydrate consumption (Zhang et al., 1998, Small et al., 2003).
Leptin, a hormone long associated with the homeostatic control of fat storage,
has more recently been shown to exert some inhibitory control over rewardrelated pathways and fat consumption (Fulton et al., 2000, Shizgal et al., 2001,
Horvath, 2003, Figlewicz et al., 2004).
Quantification of plasma leptin levels of the fat-preferring C57Bl/6 mice
and the macronutrient non-preferring BALB/c mice revealed that the former had
a significantly higher level. However, when the blood plasma was expressed as
a ratio with their total fat for both strains, it was revealed that there were no
significant differences. This indicates that the expression levels for each strain
were similar and thus the elevated plasma leptin levels seen in the C57Bl/6
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mice are simply a result of their increased fat mass. Despite the elevated
plasma leptin levels seen in the C57Bl/6 strain, these mice continued to eat at
an elevated level throughout the experiment. This suggests either the C57Bl/6
mice are comparatively less sensitive to leptin than their non-preferring
counterparts, or, the fat preference of these mice is a result of alterations in
other neuroregulatory signals. As the central administration of leptin has been
shown to preferentially decrease fat consumption, the possible differences in
leptin sensitivity between the two strains may not only account for their
disparities in total energy intake but may also account for their distinct
macronutrient preferences (Fulton et al., 2000, Figlewicz et al., 2004).
Quantification of the hypothalamic melanocortin genes revealed that
whilst there were no significant differences in POMC mRNA expression
between the two strains, The BALB/c mice had an AgRP mRNA level that was
33.6% greater than the C57Bl/6 mice. These results indicate that the C57Bl/6
mice may have had a decreased antagonism of the MC4 receptor compared to
the BALB/c mice. As leptin has been shown to inhibit the release of AgRP, the
lower levels seen in the arcuate nucleus of the C57Bl/6 mice are likely the result
of their increased plasma leptin (Mizuno and Mobbs, 1999). And yet as in situ
hybridization only measures mRNA expression, further tests need to be carried
out to determine whether the same alterations also occur in regards to protein
level and function.
Pharmacological studies have revealed that the central administration of
the MC4 receptor agonist MTII causes both a reduction in energy intake and a
decreased preferential consumption of saturated fat (Pierroz et al., 2002,
Samama et al., 2003). This taken in concert with the in situ results for the
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C57Bl/6 mice implies that these mice should have reduced their energy intake
and high fat diet preference. This however was not the case. Whilst AgRP, may
have been decreased in the C57Bl/6 mice, they continued to preferentially eat
the high fat diet at elevated levels. It is possible that AgRP expression may
have been decreased in the C57Bl/6 mice as a defensive response to their high
preferential consumption of the high fat diet. However it appears that this
defensive response was ineffectual.
One cause for the unsuccessful AgRP response seen in the C57Bl/6
may be that they had significantly elevated hypothalamic levels of Galanin
mRNA expression. Previous studies have revealed that the consumption of
diets high in fat leads to an increase in PVN hypothalamic galanin expression in
rats (Akabayashi et al., 1994). Thus the elevation of galanin expression seen in
the C57Bl/6 mice was most likely the result of their preferential high fat diet
consumption.
The positive correlation between fat intake and total energy intake seen
in the C57Bl/6 mice may also be explained by their elevated levels of galanin.
The injection of galanin into the hypothalamus has been shown to increase
energy intake (Kyrkouli et al., 1986). Furthermore this stimulatory effect on
feeding has been shown to be more pronounced and prolonged in subjects that
consume a high fat compared to low fat diet or in strains of rats that naturally
prefer fat, and it is greatly reduced when fat is removed from the diet (Tempel et
al., 1988, Barton et al., 1995, Leibowitz et al., 1998, Nagase et al., 2002). Thus
the preferential fat consumption of the C57Bl/6 mice may have driven their
elevated energy intake despite any defensive elevation of leptin. Also, as these
mice preferred to consume their calories from fat, any increases in galanin and
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energy intake may have in turn lead to an increased preferential consumption of
the high fat diet (Kyrkouli et al.). Thus galanin, acting in this positive feedback
manner may drive energy intake and weight gain when fat-preferring mice are
placed on their preferred diet.
The elevated fat mass seen in the C57Bl/6 mice may have also been
directly affected by their elevated levels of galanin. Not only does galanin cause
increases in energy intake when subjects are placed on a high fat diet, but it
also affects fat metabolism. Injection of galanin into the PVN has been shown to
increase carbohydrate metabolism and decrease fat metabolism in skeletal
muscle (Yun et al., 2005). Whilst this may serve to defend against the metabolic
disturbances and hyperglycaemia usually caused by a high fat diet, it may also
promote weight gain and obesity as less fat is metabolised and is thus stored in
adipose tissue (Yun et al., 2005).
Whilst this study examined galanin, future studies should also examine
the role of galanin-like peptide (GALP) in macronutrient preference and obesity.
GALP has been shown to be strongly involved in the hypothalamic control of
feeding and energy balance regulation however no studies have been carried
out to examine its role in macronutrient preference (Man and Lawrence 2008;
Taylor, Madison et al. 2009).
This experiment revealed distinct differences in the expression of
hypothalamic feeding signals

between

the fat-preferring C57Bl/6

and

macronutrient non-preferring BALB/c mice. However, as in situ hybridisation
only examines signal expression at the gene level, confirmation is also needed
at the protein level before any conclusions can be drawn. Also, this experiment
only examined the expression of the genes for POMC, AgRP and Galanin. As
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several other neuropeptides and receptor families such as dopamine and the
dopamine D2 receptor, the cannabinoid CB1 receptor and endogenous opioids
have all been indicated in the control of macronutrient preference, a complete
understanding of fat preference will only be gained once all these genes have
been analysed (Glass et al., 1997, Zhang et al., 1998, Odorizzi et al., 2002,
Horvath, 2003, Small et al., 2003).
In conclusion, this study has revealed that a substantial amount of
phenotypic variation exists for the preference of macronutrients among inbred
strains of mice. The revelation of a positive relationship between fat
consumption and total energy intake confirms that research into the area of fat
preference is important for the future understanding of obesity development. By
maintaining the fat-preferring C57Bl/6 mice and macronutrient non-preferring
BALB/c mice in a relatively consistent environment, it is hoped that key genes
involved in feeding and macronutrient preference will be identified. Furthermore,
whilst this experiment examined the levels of gene expression of only three
signals involved in feeding, a clear understanding of the central control of
macronutrient preference will only be gained by analysing differences in the
expression of all signals involved in fat preference at both the level of the gene
and the protein.
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Chapter 3. Drug Treatment with AM 251, Beta Funaltrexamine
and Bromocriptine in a Fat-Preferring Obese-Prone Strain of
Mouse

3.1 Introduction
When C57BL/6 mice are given a two-choice, high fat and low fat, diet,
they consume four times more high fat than low fat food (South and Huang,
2006). High fat diets are considered palatable to both humans and rodents. The
cannabinoid CB1 receptor, the dopamine D2 receptor and the opioid mu
receptor have all been implicated in palatable feeding. Studies have shown that
these receptors are co-localised in reward-related areas involved in feeding
including the nucleus accumbens and caudate putamen (Rodriguez et al., 2001,
Pickel et al., 2004, Huang et al., 2006). Also, the administration of both CB1 and
opioid mu agonists and D2 antagonists to rodents has been shown to enhance
food intake (Cincotta et al., 1997, Saper et al., 2002, Cota et al., 2006). Whilst
the opioid mu receptor, dopamine D2 receptor and cannabinoid CB1 receptor
have been implicated in palatability-related aspects of feeding, no data are
available in regards to the specific antagonism of these receptors in relation to a
two-choice high fat/low fat diet. This experiment aims to examine if these drugs
may be effective at altering the preference for and consumption of high fat diets
in fat-preferring C57Bl/6 mice fed a two-choice diet.

3.2 Materials and Methods
Forty eight, 8-week old, male C57Bl/6 mice were placed on a two-choice
high fat / low fat diet paradigm for twenty days (Table 2.1). After seven days of
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feeding, all mice were injected with saline for three days (i.p.). Following this,
mice were divided into six groups (n = 8) and injected with either the CB1
receptor inverse agonist AM 251 (5mg/kg, i.p., obtained from Tocris Bioscience,
Ellisville, MO), it’s vehicle (saline with 5% dimethyl sulfoxide and 5% Tween-80,
Sigma, St Louis, MO, i.p.), the D2 agonist Bromocriptine (6mg/kg, i.p. obtained
from Tocris Bioscience, Ellisville, MO), and its vehicle (saline with 5% Tween80, Sigma, St Louis, MO, i.p. ) and the opioid mu antagonist β-Funaltrexamine
Hydrochloride (15mg/kg, s.c., obtained from Tocris Bioscience, Ellisville, MO) or
it’s vehicle (saline, s.c.) for four days. The dosages and treatment protocols for
AM 251, Bromocriptine and β-Funaltrexamine were determined from previous
studies (Cincotta et al., 1997, Krishnan-Sarin et al., 1998, Chambers et al.,
2004). Mice then remained on the two-choice diet for a further six days and
were sacrificed. All injections were given in a volume of 10 µl/gram of body
weight/mouse. Macronutrient intakes were measured during the experiment by
weighing 24-h intakes of both diets along with the exclusion of any spillage.
Energy intake on days 1 to 5 of the two-choice diet was not measured as
baseline levels of feeding had not been reached. Energy intake results were
divided into three time periods; pre-treatment period (days 6-10), the treatment
period (days 11-14) and the post-treatment period (days 15- 20). All data was
analysed using the SPSS statistical package version 13.0 (SPSS Inc., Chicago,
Illinois). Treatment and vehicle groups were compared via a two-way repeated
measures ANOVA (treatment x time as the repeated measure). Significant
differences at each time point were then ascertained with post-hoc independent
t-tests for all comparisons.
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3.3 Results
3.3.1 AM 251 treatment
A two-way repeated ANOVA (treatment x time as the repeated measure)
revealed significant effects of treatment (F1, 14=14.784, p < 0.002) and time (F12,
144=9.974,

p<0.001) on total energy intake (Fig. 3.1 A). There was also a

significant interaction between the two factors (F12,

144=5.705,

p<0.005). No

significant differences were seen between the groups in the pre-treatment
period. However, AM 251 treatment induced an immediate decrease in total
energy intake which remained for all treatment days (-5.38< t < -8.20, d.f. = 12,
p < 0.005). Upon cessation of treatment, total energy intake returned to levels
similar to the vehicle treated controls.
Significant effects of AM 251 treatment (F1, 14=7.516, p<0.018) and time
(F12,

144=14.022,

p<0.001) were also revealed for high fat diet energy intake

(Fig. 3.1 B). Furthermore, a significant interaction between the two factors was
also found (F12,

144=6.316,

p<0.001). No differences between the two groups

were seen in the pre-treatment period. In the treatment period, an immediate
reduction in high fat diet intake was seen in the AM 251 treated mice which
remained for all four days of the treatment (-6.849 < t <-9.901, d.f. = 12, p <
0.005). High fat diet energy intake then returned immediately to normal levels
upon cessation of the treatment.
In contrast to high fat diet energy intake, there were no significant effects
of AM 251 treatment (F1, 12=0.005, p<0.942) and time (F12, 144=0.725, p<0.560)
on low fat diet energy intake (Fig. 3.1 B). Furthermore, no significant interaction
was found between the two factors (F12, 144=2.050, p<0.114).
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Figure 3.1. Total 24 hour energy intake (A), high fat and low fat diet 24 hour
energy intake (B) and fat preference (high fat intake / total energy intake; C) in
C57BL/6 mice injected with AM 251. * p< 0.05 vs. vehicle group.
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There was a significant effect of AM 251 on time (F12, 144=5.837, p<0.001)
but no significant effects of treatment (F1, 12=2.314, p < 0.154) for fat preference
(high fat diet energy intake / total energy intake; Fig. 3.1 C). However, there was
a significant interaction between time and treatment group (F12, 144 = 4.012, p <
0.001). Fat preference of the AM 251 treated mice was significantly lower than
the vehicle treated mice on the 3rd and 4th day (-5.00 < t <-9.90, d.f. = 12, p <
0.005) but not on the first 2-days of treatment (-0.73 < t < -1.16, d.f. = 12, 0.477
> p >0.269).

3.3.2 β-Funaltrexamine treatment
A two-way repeated ANOVA (treatment x time as the repeated measure)
revealed significant effects of treatment (F1,

14

= 28.012, p < 0.001) and time

(F12, 168 = 12.681, p < 0.001) and significant interaction between the two factors
(F12, 168 = 3.749, p < 0.005) on total energy intake (Fig. 3.2 A). Further post hoc
analysis revealed no significant differences between the two groups in the pretreatment period. However, during the treatment period the β-Funaltrexamine
treated mice had an immediate reduction in total energy intake which remained
for all four days of drug treatment (4.55< t < 8.74, d.f. = 14, p < 0.005).
Furthermore, the total energy intake of the β-Funaltrexamine treated mice
remained significantly lower than controls after 48 hours of treatment cessation
(t = 3.19, d.f. = 14, p< 0.006). Following this the total energy intake of the βFunaltrexamine treated mice then returned to levels similar to vehicle-treated
controls.
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Figure 3.2. Total 24 hour energy intake (A), high fat and low fat diet 24 hour
energy intake (B) and fat preference (high fat intake / total energy intake; C) in
C57BL/6 mice injected with Beta-Funaltrexamine. * p< 0.05 vs. vehicle group.
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Significant effects of treatment (F1, 14 = 17.989, p < 0.001) and time
(F12, 168 = 17.713, p < 0.001) were also revealed for high fat diet energy intake
(Fig. 3.2 B). Furthermore, a significant interaction between the two factors (time
and treatment) was also found (F12, 168 = 6.816, p < 0.001). As shown in Fig 3.2
B, no significant differences were seen between the two groups in the pretreatment period. However, β-Funaltrexamine treatment caused an immediate
reduction in high fat diet intake which remained significantly different from
controls for all four days of the treatment despite a slight increase in energy
intake on treatment days 3 and 4 (2.58 < t <12.57, d.f. = 14, 0.021 > p >
0.0005).

In the post-treatment period no significant differences were found

between the groups.
Unlike high fat diet energy intake, there were no significant effects of βFunaltrexamine treatment (F1, 14 = 1.197, p < 0.292) and time (F12, 168 = 1.658, p
< 0.152) on low fat diet energy intake (Fig. 3.2 B). Furthermore, no significant
interaction was found between the two factors (F12, 168 = 3.761, p < 0.073).
Significant effects of β-Funaltrexamine on time (F12,

168

= 7.394, p <

0.001) but no effects of treatment (F1, 14 = 0. 48, p = 0.373) were found for fat
preference (high fat diet energy intake / total energy intake; Fig 3.2C). However,
an interaction between time and treatment group (F12,

168

= 7.916, p < 0.001)

was found. Fat preference of the β-Funaltrexamine treated mice was
significantly lower than the vehicle treated mice on the first two days of
treatment (4.23 < t <9.79, d.f. = 14, p < 0.001), but then returned to normal
despite two more days of treatment.
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3.3.3 Bromocriptine treatment
A two-way repeated ANOVA (treatment x time as the repeated measure)
revealed no significant effects of treatment (F1, 14=4.092, p < 0.06) or time (F12,
168=2.116,

p<0.293) on total energy intake (Fig. 3.3 A). However, a significant

interaction between both treatment and time was found (F12,

168=15.660,

p<0.02). No differences between the two groups were seen in the pre-treatment
period. In contrast, total energy intake was reduced in the Bromocriptine treated
mice for all four days of the treatment compared to the vehicle treated mice
(2.41 < t <5.99, d.f. = 14, p < 0.03). No significant differences in total energy
intake were seen between the two groups upon cessation of the treatment.
Significant effects of Bromocriptine treatment (F1, 14=7.808, p < 0.01) but
not time (F12,

168=4.757,

p<0.11) were also revealed on high fat diet energy

intake (Fig. 3.3 B). There was also no significant interaction between the two
factors (F12,

168=4.876,

p<0.11). No significant differences were seen between

the groups in the pre-treatment period. However, Bromocriptine treatment
induced an immediate decrease in total energy intake which remained for all
treatment days (2.826< t < 6.742, d.f. = 14, p < 0.01). Upon cessation of
treatment, total energy intake returned to levels similar to the vehicle treated
controls.
In contrast to high fat diet energy intake, there were no significant effects
of Bromocriptine treatment (F1,

14=0.778,

p<0.39) and time (F12,

168=0.111,

p<0.99) on low fat diet energy intake (Fig. 3.3 B). Furthermore, no significant
interaction was found between the two factors (F12, 168=0.363, p<0.91).
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Figure 3.3. Total 24 hour energy intake (A), high fat and low fat diet 24 hour
energy intake (B) and fat preference (high fat intake / total energy intake; C) in
C57BL/6 mice injected with Bromocriptine. * p< 0.05 vs. vehicle group.
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No significant effects of Bromocriptine on time (F12, 168 = 0.817, p < 0.66)
or treatment (F1, 14 = 3.246, p < 0.09) were found for fat preference (high fat diet
energy intake / total energy intake; Fig 3.3C). Furthermore, no interaction
between time and treatment group (F12, 168 = 0.77, p < 0.681) was found.

3.4 Discussion
3.4.1 AM 251treatment
Treatment of the C57BL/6 mice with the CB1 inverse agonist AM 251
confirmed this receptor’s relationship with energy intake. In agreement with
previous studies, peripheral injection of AM 251 was found to cause a
significant decrease in total energy intake in the C57Bl/6 mice (Hildebrandt et
al., 2003, Chambers et al., 2004). Furthermore, this study is the first to reveal
that the peripheral administration of AM 251 causes a preferential reduction of
high fat diet consumption in a fat-preferring strain of mouse. Fat preference of
the treated mice was found to be significantly lower than the vehicle-treated
controls. This finding supports previous work showing that CB1 receptors are
not only involved in satiety but also in the rewarding aspects of feeding (Brown
et al., 1977, Di Marzo et al., 2001, Ravinet Trillou et al., 2003). One study by
Chaperon et al. has shown that the CB1 antagonist SR 141716 reduces the
conditioned place preference for lab chow and sucrose pellets (Chaperon et al.,
1998). Another study by Arnone et al. has shown that administration of
SR141716 causes a selective reduction in the consumption of palatable
sucrose pellets (Arnone et al., 1997).
It should be noted that Verty et al. have shown that the treatment of rats
with the CB1 antagonist SR 141716 reduces energy intake regardless of
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palatability (Verty et al., 2004). However, the rats in their study were placed on
single-choice diets and thus SR 141716’s effects on macronutrient preference
on a two-choice paradigm could not be determined. One experiment by
McLaughlin et al. revealed that administration of the CB1 inverse agonists SR
141716 and AM 251 to rats caused a decrease in food intake on a three-choice
diets (high fat, high carbohydrate and lab chow) with no effects on preference
(McLaughlin et al., 2003). And yet, the dissimilarities of these results to those of
the present study may be accounted for by differences in the species used, the
diet paradigms and the baseline macronutrient preferences of the strains used
in each experiment.
In an experiment by De Vry et al. it was revealed that whilst the CB1
inverse agonist SR141716A reduced operant responding for palatable foods it
was also found to cause conditioned taste aversion (De Vry et al., 2004). This
raises the possibility that the reduced fat preference seen in the present
experiment may be due to taste aversion. However, the dosage used in De Vry
et al’s experiment was much higher (10mg/kg) and in another experiment where
the dose of SR 141716A was lower (3mg/kg), no conditioned place aversion
occurred (Chaperon et al., 1998). Furthermore, an experiment by Chambers et
al. that used both the same CB1 inverse agonist and dosage rates (AM 251, 3-5
mg/kg) that were used in the present experiment found no conditioned taste
aversion following administration to rats (Chambers et al., 2006). Thus it
appears likely that reductions in energy intake following AM251 treatment are
not attributable to feelings of malaise.
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3.4.2 Beta-Funaltrexamine treatment
Like AM 251, treatment of the fat-preferring C57Bl/6 mice with the
irreversible opioid mu receptor antagonist β-Funaltrexamine confirmed this
receptor’s relationship with feeding as it caused a significant reduction in energy
intake. Other studies have revealed that intraventricular administration of βFunaltrexamine causes a reduction in free- feeding and fasting and glucoprivic
induced feeding (Ukai and Holtzman, 1988, Ragnauth et al., 1997). Work by
Arjune et al. has also revealed that the peripheral administration of βFunaltrexamine causes a reduction in energy intake that lasts up to 72 hours
following treatment (Arjune et al., 1990).
It should be noted that only the preferred diet of the C57Bl/6 mice was
decreased in this experiment with no concomitant decrease in the low fat diet.
This suggests antagonism of the opioid mu receptor elicits it’s affects by
reducing the motivation for a preferred diet. This finding agrees with work by
Gosnell et al. which has revealed that morphine enhances carbohydrate intake
in carbohydrate-preferring rats, and increases fat intake in fat-preferring rats
(Gosnell et al., 1990). Furthermore, morphine only stimulates fat intake when a
preferred lipid type (vegetable shortening) is presented as apposed to a nonpreferred lipid type (corn oil) (Glass et al., 1999).This suggests that opioid
stimulation does not specifically enhance consumption of a palatable diet but it
enhances the consumption of a preferred diet. Thus the decrease in fat
consumption seen following peripheral administration of β-Funaltrexamine may
have been a result of the baseline macronutrient preference of the C57 mice.
Further work examining the effects of β-Funaltrexamine on high fat diet
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preference in carbohydrate-preferring and macronutrient non-preferring mice
will help elucidate whether this is the case.
Pharmacological studies that specifically target the opioid mu receptor
have further clarified its role in fat preference. Work by Zhang et al. has shown
that the direct injection of the opioid mu receptor specific agonist DAMGO into
the nucleus accumbens specifically increased high fat diet intake over high
carbohydrate diet intake regardless of baseline dietary preference (Zhang et al.,
1998). This finding suggests opioid mu receptors in the nucleus accumbens
may directly control fat selection rather than macronutrient preference. Another
study by Naleid et al. has shown that direct infusion of the opioid mu receptor
specific agonist DAMGO into the shell of the nucleus accumbens and
hypothalamic paraventricular nucleus preferentially increases high fat diet
consumption over sucrose in fat-preferring rats (Naleid et al., 2007). No
changes in diet preference were seen in the sucrose preferring rats following
DAMGO infusion. This finding suggests that opioid mediated food intake may
not only be governed by baseline macronutrient preferences but also by the
macronutrient type itself.

3.4.3 Bromocriptine treatment
Bromocriptine treatment was found to reduce high fat diet energy intake,
and consequently total energy intake, with no change in low fat diet intake in the
fat-preferring C57Bl/6 mice. Despite a reduction in high fat diet intake no
alterations in fat preference were found. Other studies have similarly revealed
that Bromocriptine treatment can reduce energy intake in rodents (Carruba et
al., 1980, Zarrindast et al., 1991, Mardones and Quintanilla, 1996, Cincotta et
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al., 1997). Furthermore, it has been shown that Bromocriptine-induced anorexia
is reversed by D2 antagonist (Pimozide) treatment (Zarrindast et al., 1991). This
supports the likelihood that Bromocriptine’s anorectic effects are mediated by its
D2 receptor agonist properties.
In contrast to the present findings, other studies have revealed
Bromocriptine enhances food intake in mice (Brien, 1986). Whilst other studies
have found that administration of a D2 agonist to rats has no effect on
deprivation-induced food intake (Hobbs et al., 1994). The disparity of results for
D2 agonists and feeding may be explained by the role of dopamine in feeding.
Dopamine is released in a transient and regulated manner during feeding and
any disruption of this process has been shown to lead to hypophagia (Sotak et
al., 2005). It is hypothesised that at some doses, D2 agonists may bind
continuously to the receptor and interfere with its ability to recognise fluctuations
in natural dopamine release during feeding (Beninger and Miller, 1998). Thus, in
some cases, a D2 agonist may have an action that is similar to a D2 antagonist.
The dose used for dopamine D2 agonists may be very important for
influencing food intake and may explain why different studies have produced
conflicting results. In one study it was found that an intraperitoneal injection of a
D2 receptor agonist (N-0437) at a low dose caused an increase in food intake,
a moderate dose had no effect, whilst a high dose reduced food intake (Clifton
et al., 1989). It is possible that these different doses may differentially alter
dopamine release in feeding related brain areas. One study has shown that
high and low doses of Bromocriptine have different effects on striatal dopamine
release in vivo (Brannan et al., 1993). A low and moderate dose of
Bromocriptine (2.5 and 5 mg/kg) was shown to decrease extracellular levels of
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dopamine whilst a high dose (10 mg/kg) was shown to cause an increase. Thus
it appears the dose of Bromocriptine used may be an important determining
factor for its effects on striatal dopamine levels and subsequent food intake.
The site of action may also be an important factor for determining the D2
receptor’s role in food intake. Whilst peripheral administration of Bromocriptine
has been shown to reduce food intake, direct infusion into the striatum has the
opposite effect (Inoue et al., 1997). Furthermore, Bromocriptine infusion into this
brain area was found to have no effects on dopamine levels (Inoue et al., 1997).
This raises the likelihood that Bromocriptine’s stimulatory effect on feeding in
the striatum is mediated via post-synaptic D2 receptors.
This study found Bromocriptine reduced high fat diet intake with no
change in low fat diet intake. It is possible that this specific reduction in high fat
diet intake may have occurred due to a reduction in its perceived palatability.
Administration of another D2 agonist, quinpirole, to food-deprived rats has been
shown to eliminate the preference of a palatable high fat high sugar diet
(Cooper and Al-Naser, 2006). And yet, no significant alterations in fat
preference were found in the present study. It is possible that the dose of drug
used in the current experiment may not have been appropriate for the alteration
of macronutrient preference. Also, the low baseline consumption of the low fat
diet by the C57Bl/6 mice may have made it difficult to uncover alterations in fat
preference. Future studies that use mice with a lower fat preference in
conjunction with varied doses may help to further clarify Bromocriptine’s effects
on macronutrient preference.
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3.4.4 Conclusions
This study has shown that the CB1 inverse agonist AM 251, the opioid
mu antagonist β-Funaltrexamine and the D2 receptor agonist Bromocriptine
similarly reduce total energy intake via a specific reduction of high fat diet
energy intake. Both AM 251 and β-Funaltrexamine were found to affect fat
preference but Bromocriptine did not. Whilst both AM 251 and β-Funaltrexamine
were found to reduce fat preference, differences in the time course of these
changes were seen. Reductions in fat preference occurred immediately upon
initiation of β-Funaltrexamine treatment however this was abolished after day 2
despite further drug administration. In contrast, reductions in fat preference for
the AM 251 treated mice were not seen until days 3 and 4 of treatment. This
suggests that unlike β-Funaltrexamine, some time may be required for this
drugs effect on macronutrient preference to be seen. However, a better
understanding of the effects of all three drugs may be gained in future studies
by altering the treatment period, dosage rate and baseline macronutrient
preference of the mice to be used.
Currently, the rates of obesity are climbing ever higher on a worldwide
scale. Furthermore, the numbers of pharmacological treatments for this disorder
remain few. Thus the opioid mu receptor, CB1 receptor and D2 receptor are
exciting targets for the treatment of obesity as they are not only effective at
reducing total energy intake but can also reduce the consumption of a preferred
obesogenic high fat diet. And yet, given the broad distribution of these receptors
throughout the brain, the physiological and psychological aspects of these drug
treatments will also need to be assessed. A more effective future means of
acting on these palatable feeding-related receptors may be to treat them
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simultaneously. The resulting synergistic effects of this combined treatment on
energy intake would allow the use of lower dosages which would in turn
decrease the potential for negative side effects.
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Chapter 4: Peripheral Data for Short and Long-Term High Fat
Diet-Induced Obesity in C57Bl/6 Mice.

4.1 Introduction
A high fat diet was administered to the C57Bl/6 mice for three and twenty
weeks to compare phenotypic differences in the early and late stages of
obesity. Also, mice were fed a high fat diet for three weeks and then switched to
a low fat diet for one and seven days in order help determine how acute
alterations in energy intake and macronutrient type can affect the expression of
signals and receptors related to energy balance.

4.2 Materials and Methods
4.2.1Housing
Mice were obtained from the Animal Resources Centre (Perth, Western
Australia). All mice were housed individually in an environmentally controlled
◦

room (22 C, 06:00-18:00 light, and 18:00-06:00 dark). All mice were given ad
libitum access to water and food throughout the experiment. Mice were first fed
standard laboratory chow for the first week in order to acclimatize them to their
new surroundings.

4.2.2 Animals
Sixty 8-week old male C57Bl/6 mice were divided randomly into six
separate groups (n=10). Thirty mice were fed the high fat diet for three weeks
and ten mice were fed the low fat diet for three weeks as controls (Table 2.1).
After three weeks of feeding, ten LF fed mice and ten HF fed mice were
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sacrificed. The remaining HF fed mice were placed on the LF diet. After one day
and seven days of LF feeding ten mice were sacrificed at each time point. To
examine the long term effects of obesity on C57Bl/6 mice, 10 mice were given
ad libitum access to a high fat diet for twenty weeks and ten mice were fed a
low fat diet for the same period as controls. Macronutrient intakes were
determined during the experiment by weighing 48-hr intakes of both diets along
with the exclusion of any spillage. Body weight was measured every two days of
the experiment. All experimental procedures were approved by the Animal
Ethics Committee University of Wollongong, and complied with the Australian
Code of Practice for the Care and Use of Animals for Scientific Purposes.

4.2.3 Serum Leptin Radioimmunoassay
Mice were sacrificed and their blood was collected via right ventricle
puncture. The blood samples were centrifuged at 4000rpm for ten minutes. The
plasma was then carefully removed from the packed hematocrit and stored at 20ºC. Serum leptin was then determined by using a Linco RIA kit for Rat leptin
(Linco Research, Inc. USA).

4.2.4 Histology
Mice were killed with an overdose of sodium pentobarbitone (120mg/kg,
i.p.). All mice were killed between 07:00 and 09:00 in order to minimize
circadian variation of possible neurotransmitter changes. Upon sacrifice of all
mice, brains were removed and frozen in liquid nitrogen. Coronal brain sections
(14µm) were cut at -17oC with a cryostat and thaw mounted onto PolysineTM
Microscope Slides (Menzel GmbH & Co. KG, Braunschweig).
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4.2.5 Statistical Analysis
Data from all experiments was analysed using the SPSS statistical
package (SPSS, Chicago, IL, USA). Comparisons between groups were
performed via one-way ANOVA and significant phenotype differences were then
ascertained with post-hoc Tukey-Kramer-HSD tests for multiple comparisons.

4.3 Results
The C57Bl/6 mouse strain was fed a high fat diet for three weeks which
was then replaced with a low fat diet for one and seven days. In the 3wk
HF+1day LF and 3wk HF+7day LF groups there was a significant drop in
energy intake after one day of replacement of the high fat diet with the low fat
diet (31.5% and 38.9% respectively (Table 4.1). Furthermore, the energy intake
of the 3wk HF+1day LF group remained significantly lower throughout the low
fat feeding period compared to the high fat feeding period.
When the final body weight (FBW) of the 3wk LF group was compared to
the other three groups, it was found there was a statistically significant
difference among the groups [F(3, 24)=6.96, p=0.002]. Further post-hoc
comparisons revealed that the FBW of the 3wk LF group was significantly lower
than all the other groups (9.0% vs. 3wk HF, 11.4% vs. 3wk HF+1day LF and
9.0% vs. 3wk HF+7days LF). No other significant differences were found among
the high fat fed groups for FBW. The three high fat fed groups were also found
to have significantly more visceral fat compared to the low fat fed mice
([F(3,23)=7.78, p=0.001], 56% vs. 3wk HF, 84% vs. 3wkHF+1dayLF and 72%
vs. 3wk HF+7days LF).
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Table 4.1. Peripheral data of C57BL/6 mice following three weeks of high fat
diet consumption, three weeks of low fat diet consumption and three weeks
high fat diet consumption followed by one and seven days of low fat diet
3wkHF
3wkLF
3wkHF +
3wkHF +
1dayLF
7daysLF
Final body
27.43±0.54a
25.00±0.29
28.23±0.58a
27.57±0.69a
weight
(grams)
Plasma
2.92±0.47
1.92±0.21
4.24±0.72a
4.74±0.54a
leptin (ng/ml)
energy
15.89±0.62
17.31±0.50
11.30±0.33b
13.760±0.64b
intake*
Visceral fat
0.80±0.04a
0.51±0.02
0.94±0.08a
0.88±0.10a
(grams)
Data are expressed as means ± S.E.M. a p < 0.05 vs. 3WK LF, b p < 0.05 vs.
3WK HF & 3WK LF. *:Final 24 hr energy intake (kcal)

Radioimmunoassay was performed on the blood of the four different
groups to determine their plasma leptin levels. Upon quantification it was shown
that the 3wk HF+1dat LF and the 3wkHF+7days LF groups had plasma leptin
levels that were 120.3% and 147.4% greater than the 3wk LF group
respectively [F(3,23)=6.05, p=0.004](Table 4.1).
The mice fed a high fat diet for twenty weeks also were found to have a
significantly elevated body weight gain (343.3%, [F(1,10)=543.55, p=0.0001]),
final body weight (68.9%, [F(1,10)=785.70, p=0.0001]), visceral fat pad mass
(738.3%, [F(1,10)=684.49, p=0.0001]), and average 24 hour energy intake
(15.93%, [F(1,10)= 11.14, p=0.007]) compared to the mice fed the low fat diet
for twenty weeks (Table 4.2).
Radioimmunoassay for plasma leptin was also performed on the blood of
the mice fed the diets for twenty weeks (Table 4.2). The twenty-week high fat
fed mice were found to have plasma leptin levels that were elevated to an even
greater extent compared to the twenty-week low fat fed mice (850.4%,
[F(1,10)=120.54, p=0.0001]).
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Table 4.2. Body weight, visceral fat mass, plasma leptin and energy intake
of C57Bl/6 mice fed a high fat or low fat diet for twenty weeks
Plasma
Average 24
Final
body leptin
hr
energy Visceral fat
weight (grams) (ng/ml)
intake (kcal)
(grams)
*
*
*
*
24.34±1.95
21.82±18.83
6.29±0.18
20 week HF 45.33±0.62
20 week LF 26.83±0.22
2.56±0.37
18.83±0.35
0.75±0.11
*
Data are represented as mean ± S.E.M. p < 0.05 vs. 20 week LF group

4.4 Discussion
Replacement of the preferred high fat diet with the less preferred low fat
diet following three weeks of feeding caused a notable increase in plasma
leptin, whilst energy intake was reduced. No significant changes occurred for
body weight following diet replacement although the 3wk LF group was found to
be significantly lower than all three HF fed groups.
The negative effects of a high fat diet on body weight were further
highlighted in the current experiment. The 3wk LF group was found to have a
final bodyweight that was significantly lower than the high fat fed groups.
Interestingly, this difference in final body weight occurred despite the fact that
energy intakes were similar for the 3wk HF and 3wk LF groups. This may be
due to the fact that high fat diet-induced weight gain has been shown to be not
only due to differences in energy intake. In a study by Oscai et al., rats fed a
high fat diet weighed 128% more than rats fed lab chow despite the fact that no
differences in energy intake were detected over 60 weeks for the two groups
(Oscai et al., 1984). A study by Boozer et al. has revealed that isocaloric
increases in dietary fat levels cause parallel increases in adiposity in rats
(Boozer et al., 1995). Another study has revealed that C57Bl/6J mice that are
pair-fed a high fat diet with energy intake levels that are identical to low fat
controls, still have an elevated final body weight and an increased fat mass
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(Petro et al., 2004). These findings suggest fat intake has an effect on weight
gain that is independent of caloric intake.
In conjunction with their lower final body weight, the 3wk LF group was
found to have the lowest plasma leptin levels. Interestingly, when mice that had
been fed a high fat diet for three weeks were switched to a low fat diet for one
and seven days, there was a dramatic increase in their plasma leptin levels.
Two cooperating factors may be responsible for the elevated plasma leptin
levels seen in the 3wk HF+1day LF and 3wk HF+7day LF groups. Firstly, like
the 3wk HF group, the 3wk HF+1 day LF and 3wk HF+7day LF groups had an
elevated final body weight compared to the 3wk LF group and thus their leptin
was elevated as a defensive response to decrease their fat mass (Lin et al.,
2000). Secondly, the consumption of low fat/high carbohydrate diets have been
shown to be better at promoting leptin secretion (Romon et al., 1999, Romon et
al., 2003). This explains why the 3wk HF + 1day LF and 3wk HF+7day LF
groups had higher leptin levels than the 3wk HF group despite their similar final
body weight levels.
The elevated plasma leptin levels of the 3wk HF+1day LF and 3wk
HF+7day LF groups may also explain their decreased energy intake following
the switch from high fat to low fat diets. The elevated leptin levels in these mice
would have lead to stimulation of anorexigenic and inhibition of orexigenic
pathways of the brain thus leading to an enhanced feeling of satiety and
decreased sensation of reward (Figlewicz, 2003). Another explanation for the
drop in energy intake following high fat diet replacement may simply be that the
mice found the low fat diet less palatable. Consumption of a diet low in
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palatability would lead to a decrease in the stimulation of the brains rewardrelated pathways thus leading to a decrease in the motivation to feed.
Interestingly, the energy intake of the 3wk HF+7day LF mice rose
towards levels similar to the 3 wk HF group by day seven of the diet reversal.
This happened despite further increases in their plasma leptin levels. This
increase in energy intake may be explained by the presence of the many other
redundant energy intake regulators that exist both peripherally and centrally.
Following twenty weeks of high fat feeding the C57Bl/6 mice became
obese in a manner similar to what has been previously described (Lin et al.,
2000). The high fat fed mice were hyperphagic, hyperleptinemic and had an
elevated body weight accompanied by elevated levels of visceral fat compared
to the low fat fed controls. The elevated plasma leptin levels seen in the twenty
week high fat fed mice is most likely an indication of central leptin insensitivity
which may be a contributory factor for their hyperphagia and elevated fat mass
(Lin et al., 2000).
In conclusion, C57Bl/6 mice were found to become progressively obese
when fed a high fat diet. The mice fed a high fat diet for three weeks had similar
energy intake and plasma leptin levels to the low fat fed controls suggesting this
early stage of obesity may be characterised by a defensive response against
body weight gain. However, the mice fed a high fat diet for twenty weeks were
hyperphagic and hyperleptinemic compared to low fat fed controls raising the
likelihood that this late stage of obesity constitutes a defensive failure against
positive energy balance. The next three chapters will examine how the
cannabinoid CB1 receptor, opioid mu receptor, dopamine D2 receptor and
dopamine transporter are involved in these two stages of obesity. The
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dopamine D2 receptor and transporter will not be examined following twenty
weeks of high fat feeding in the current study as it has already been examined
in this mouse model (Huang et al., 2006).
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Chapter 5. Temporal and Site Specific Changes of Cannabinoid
CB1 Receptor in Fat-preferring Diet-induced Obese C57Bl/6
Mice

5.1 Introduction
The administration of CB1 antagonists to rodents has also been shown to cause
a decreased preference for rewards such as ethanol, sucrose and palatable
foods as well as a decreased energy intake (Arnone et al., 1997, Ravinet Trillou
et al., 2003, Mathes et al., 2008). These findings suggest that the CB1 receptor
may be heavily involved in the motivational drive for palatable feeding.
Whilst previous studies have examined CB1 binding in chronically obese
rodents fed a sweet palatable diet (Harrold et al., 2002), no studies have
examined CB1 binding in the early and late stages of high fat diet-induced
obesity. This experiment aimed to examine the response of the CB1 receptor to
three weeks high fat feeding as our previous work has revealed that this time
period corresponds to an early stage of obesity development in C57BL/6 mice
(Lin et al., 2000). Furthermore, this experiment also examined C57Bl/6 mice
that had been fed a high fat diet for twenty weeks. Mice fed a high fat diet for
this period of time are in the late stage of obesity which is characterised by
hyperphagia and central leptin insensitivity (Lin et al., 2000). Finally, CB1
receptor binding was also examined in mice that had been fed a high fat diet for
three weeks and then fed a low fat diet for one or seven days. This was done to
determine how the CB1 receptor responds to short term alterations in energy
intake and macronutrient type
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5.2 Materials and Methods
5.2.1 Cannabinoid CB1 receptor autoradiography and quantification
Binding of [3H] CP-55,940 was used to assess binding density of CB1
receptor. Sections were allowed to defrost and then preincubated for thirty
minutes in Tris-HCl buffer (5% Bovine Serum Albumin, 50mM Tris-HCl, pH 7.4)
at room temperature. The binding sites of CB1 receptor were defined with 10nM
[3H] CP-55,940. Non-specific binding was determined in the presence of 10µM
CP-55,940. Following incubation for two hours at room temperature, slides were
washed for 1 hour and then 3 hours in ice cold buffer (1% Bovine serum
albumin, 50mM Tris-HCl, pH 7.4) and then finally washed for a further five
minutes in buffer containing no bovine serum albumin. Slides were then dipped
briefly in ice-cold distilled water and dried under a gentle stream of cool air.
Slides were stored overnight in desiccators, and then apposed for five weeks to
Tritium sensitive film for four weeks. Autoradiographs were developed using
Kodak D-19 developer and fixed with Ilford Hypam Rapid Fixer.
Autoradiographic images were captured and analysed using a computerassisted image analysis system, Multi-Analysis, connected to a GS-690 Imaging
Densitometer (Bio-Rad, USA). The density of binding was calculated by
converting the optical density of the image to nCi/gram with the aid of a
standard curve generated with calibrated microscales. The distribution of CB1
receptor binding sites in individual brain nuclei was determined from Bregma
2.22mm to Bregma -3.28mm using a standard mouse brain atlas (Paxinos and
Franklin, 2002). The striatum was divided into rostral (Bregma: 1.54 to
0.50mm), and caudal (Bregma: -0.10 to -0.82mm) according to a method used
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previously (Huang et al., 2005). Furthermore, the sections of rostral and caudal
striatum were divided into two parts (dorsal and ventral).

5.2.2 Statistical Analysis
Data from all experiments was analysed using the SPSS statistical
package (Chicago, IL, USA). Comparisons between the high fat and low fat
groups fed at three weeks and also at twenty weeks were performed via OneWay ANOVA. As seventeen brain areas were examined at each time point, the
chance of a type-1 error was increased due to the large amount of tests.
Therefore a Bonferroni adjustment was performed to adjust the alpha level from
0.05 to 0.003 (0.05 divided by 17, the number of tests performed).

5.3 Results
Upon completion of the experiment, ligand binding autoradiography was
performed for the CB1 receptor for the groups fed the high fat and low fat diets
for three and twenty weeks (Fig. 5.1 and Fig. 5.2). Autoradiography showed
[3H]CP-55,940 binding in the 3 week fed mice was significantly different in the
anterior olfactory nuclei (22.1% [F(1, 10)= 224.10, p=0.0006]), the agranular
insular cortex (24.0% [F(1, 10)= 17.47, p=0.002]), and the hypothalamus
(30.8% [F(1, 10)= 26.93, p=0.0004]). Further post-hoc analysis revealed that
the [3H] CP-55,940 binding of the mice fed the high fat diet for three weeks was
higher than the low fat fed controls in the anterior olfactory nuclei (22.1%),
agranular insular cortex (24%) and hypothalamus (30.8%). Furthermore,
replacement of the high fat diet with the low fat diet for one and seven days
caused no significant alterations in [3H] CP-55,940 binding throughout the
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brains of both groups. Consequently, the [3H] CP-55,940 binding of the 3wk +
1day LF and 3wk + 7days LF mice was found to be elevated in the anterior
olfactory nucleus (31.7% & 30.3% respectively), agranular insular cortex (26.5%
&

30.1% respectively) and hypothalamus (29.7% & 32.0% respectively)

compared to the mice fed the low fat diet for three weeks.
The CB1 binding density of the mice fed the high fat diet for twenty
weeks was found to be lower in the substantia nigra and ventral tegmental area
compared to the mice fed a low fat diet for 20 weeks (12.8% [F(1, 10)=24.52,
p=0.001] and 17.1% [F(1, 10)=38.28, p=0.0002] respectively, Fig 5.3).
Analysis of CB1 receptor binding revealed positive correlations between
final body weight and plasma leptin in the hypothalamus (Final body weight: R =
0.68 , p = 0.001 , Leptin: R = 0.79 , p = 0.001), agranular insular cortex (Final
body weight: R = 0.53, p = 0.01, Leptin: R = 0.47 , p = 0.02) and anterior
olfactory nucleus(Final body weight: R = 0.57, p = 0.005, Leptin: R = 0.51 , p =
0.01) for the mice fed the diet for three weeks.
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Fig. 5.1. Photographs depict areas of [3H] CP-55,940 binding at levels of (A, D)
Bregma 0.86 mm, (B, E) Bregma -1.46 mm and (C, F) Bregma -3.4 mm. in
C57Bl/6 mice fed a high fat diet for three weeks. Images A, B and C were
adapted from (Paxinos and Franklin, 2002). Acb: Nucleus Accumbens, Amg:
Amygdala, CPu: Caudate Putamen, GP: Globus Pallidus, Hipp: Hippocampus,
Hyp: Hypothalamus, SN: Substantia Nigra.
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Fig. 5.2. Specific [3H] CP-55,940 binding in the brains of C57Bl/6 mice high fat
diet for three weeks (3wk HF), a low fat diet for three weeks (3wk LF), or a high
fat diet for three weeks followed by a low fat diet for one (3wk HF+ 1day LF)
and seven days (3wk HF + 7days LF). Error bars represent SEM. * p<0.003 vs.
LF. Abbreviations; AI, agranular insular cortex. AO, anterior olfactory nucleus.
MO, medial orbital cortex. ACB, Nucleus accumbens. CPu R-D, rostral dorsal
caudate putamen. CPu R-V. rostral ventral caudate putamen. CPu C-D, caudal
dorsal caudate putamen. CPu C-V, caudal ventral caudate putamen. SN,
substantia nigra. VTA, ventral tegmental area.
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Fig. 5.3. Specific [3H] CP-55,940 binding in the brains of C57Bl/6 mice following
twenty weeks of high fat or low fat feeding. Black bars; high fat fed group (HF),
white bars; low fat fed group (LF). Error bars represent SEM. * p<0.003 vs. LF.
Abbreviations; AI, agranular insular cortex. AO, anterior olfactory nucleus. MO,
medial orbital cortex. ACB, Nucleus accumbens. CPu R-D, rostral dorsal
caudate putamen. CPu R-V. rostral ventral caudate putamen. CPu C-D, caudal
dorsal caudate putamen. CPu C-V, caudal ventral caudate putamen. SN,
substantia nigra. VTA, ventral tegmental area.
Page 103

5.4 Discussion
This experiment examined CB1 receptor binding in C57BL/6 mice that
were fed either a high fat diet for three weeks, a low fat diet for three weeks or
fed a high fat diet for three weeks and then changed to a low fat diet for one or
seven days. It also examined central CB1 receptor binding in C57Bl/6 mice fed
a high fat or low fat diet for twenty weeks. The main findings were: (1) high fat
diet consumption for three weeks significantly increased CB1 receptor binding
in the anterior olfactory nucleus, agranular insular cortex and the hypothalamus;
(2) Replacement of the high fat diet after three weeks with the low fat diet for
one and seven days did not affect CB1 receptor binding as it remained
significantly greater than the 3 week low fat fed mice in the anterior olfactory
nucleus, agranular insular cortex and hypothalamus. (3) Differences in these
areas disappeared after twenty weeks of high fat diet consumption however
CB1 receptor binding density was significantly decreased in the substantia nigra
and ventral tegmental area.
This study found that mice that had been fed a high fat diet for three
weeks had higher CB1 receptor binding in the anterior olfactory nucleus,
agranular insular cortex and the hypothalamus compared to the low fat fed
controls. Furthermore the mice fed a high fat diet for twenty weeks were found
to have significantly decreased binding in the substantia nigra and the ventral
tegmental area. As G-coupled protein receptors have been shown to be
inversely related to endogenous ligand levels, it is possible that the elevated
CB1 binding levels seen in the three-week high fat fed mice and the decreased
CB1 binding seen in the twenty-week high fat fed mice may be a result of lower
and higher endocannabinoid release respectively.
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It should be noted that the ligand used in this experiment ([3H] CP55,940) is an agonist and thus the alterations seen in binding density in this
experiment may be representative of either receptor density or receptor
function. As a result, future studies should also examine agonist stimulated [35S]
GTPγS binding to determine if any alterations in CB1 receptor function have
also occurred. Nevertheless, both higher levels of endocannabinoid ligand and
chronic

cannabinoid

agonist

treatment

are

associated

with

parallel

compensatory decreases in CB1 receptor density, receptor mRNA expression
and G-protein subunit expression (Rubino et al., 1994, Rubino et al., 1997,
Hansson et al., 2006, Sim-Selley et al., 2006). Thus the higher CB1 binding
seen in the three-week HF group and the lower CB1 binding seen in the twentyweek HF group may still be a result of lower and higher endogenous ligand
levels respectively regardless of whether it is indicative of receptor density or
function.
The CB1 agonist ([3H] CP-55,940) used in this study has similar affinity
to both the CB1 and CB2 receptors raising the possibility that the present
results may have been affected by CB2 receptor expression (Pertwee, 1999).
However, whilst it is accepted that the CB1 receptor is expressed abundantly in
the brain, the central expression of the CB2 receptor is much more
controversial. One study that used immunohistochemical staining revealed that
the CB2 receptor is expressed centrally in areas such as the striatum, thalamic
nuclei, hippocampus, amygdala and substantia nigra (Gong et al., 2006). And
yet, it appears CB2 receptors may be expressed at a concentration that is much
lower than CB1 receptors. Indeed, one study that used Northern blot analysis
was unable to detect any CB2 mRNA centrally (Griffin et al., 1999).
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Furthermore, through the use of a CB2 receptor specific antagonist SR144528
Griffin et al. revealed that the CB2 receptor is expressed at a level much lower
than the CB1 receptor (Griffin et al., 1999). Thus, whilst the CB2 receptor
cannot be completely discounted from the present results, the alterations in [3H]
CP-55,940 are more likely to be a result of alterations in the CB1 receptor due
to it’s much more abundant central expression.
The elevated CB1 binding seen in the hypothalamus of the three-week
high fat-fed mice may be a result of their elevated leptin levels. Indeed a
positive correlation was found between CB1 binding and plasma leptin in the
hypothalamus of the mice. Acute administration of leptin to both normal and
ob/ob mice causes a decrease in hypothalamic anandamide and 2-arichidonyl
glycerol (Di Marzo et al., 2001). Also, defective leptin signalling is associated
with increased levels of hypothalamic endocannabinoids in ob/ob and db/db
mice and Zucker rats (Di Marzo et al., 2001). Further studies have shown that
leptin

modulates

the

activity of

lateral hypothalamic

neurons

in

an

endocannabinoid dependant manner (Jo et al., 2005). Thus the higher levels of
leptin seen in the three high fat fed groups may have decreased hypothalamic
endocannabinoid levels and thus caused a compensatory increase in CB1
receptor levels. Interestingly, alterations in hypothalamic CB1 binding
disappeared at twenty weeks of high fat feeding. This period has previously
been associated with central leptin insensitivity in these mice and thus may
explain why this happened (Lin et al., 2000).
The mice fed a high fat diet for three weeks were also found to have
significantly higher CB1 binding in the agranular insular cortex and anterior
olfactory nucleus. The olfactory nucleus and agranular insular cortex are related
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to the olfactory and gustatory aspects of ingestive behaviour respectively
(Sewards, 2004). Thus, the sensory properties of the high fat diet may have
altered CB1 expression in the chronically high fat fed mice in these areas
related to taste and olfaction. Following twenty weeks of feeding, the differences
that were seen between the LF and HF groups in the anterior olfactory nucleus
and agranular insular cortex disappeared. This may be indicative of adaptation
to the high fat diet in these brain areas.
Replacement of the high fat diet after three weeks of feeding with the low
fat diet for one and seven days caused no significant alterations in CB1 receptor
binding. As a result, [3H] CP-55,940 binding remained elevated compared to
the low fat fed controls in the agranular insular cortex, anterior olfactory nucleus
and hypothalamus. Thus it seems the alterations in diet macronutrient content
and energy intake that occurred following high fat diet replacement had no
effect on CB1 receptor binding. This suggests alterations in CB1 receptor levels
may be altered by changes in long term energy balance rather than acute
alterations in energy intake and macronutrient type.
Whilst the CB1 binding differences seen in week three disappeared at
week twenty, a significant decrease in CB1 receptor binding was seen in the
substantia nigra and ventral tegmental area of the high fat fed group. The
substantia nigra is related to motor activity and reward-based learning whilst the
ventral tegmental area is involved in reward (Rosell and Gimenez Amaya, 2000,
Zangen et al., 2006). Furthermore, the ventral tegmental area projects to the
nucleus accumbens, a key brain area for natural reward (Gardner, 2005).
Stimulation of CB1 receptors in the VTA has been shown to elicit dopamine
release leading to the sensation of reward (Gardner, 2005). Thus decreased

Page 107

CB1 receptor binding in the substantia nigra and ventral tegmental area may be
indicative of an increased release of endocannabinoids due to the chronic
consumption of the palatable high fat diet. Furthermore this increased
endocannabinoid activity in these reward-related areas may help drive the
increased energy intake that is seen in the later stages of obesity in these mice.
The reduced CB1 binding seen in the obese C57Bl/6 mice is similar to
previous work by another group showing that chronic palatable feeding leads to
downregulation of extrahypothalamic CB1 receptors with no change in
hypothalamic CB1 receptor expression (Harrold et al., 2002). And yet, whilst
both the present study and that of Harrold et al.’s found a downregulation of
CB1 receptors, the site-specific locations differ. This may be because the rats
used in Harrold et al.’s experiment were fed a diet that differed in both
macronutrient content and palatability containing high amounts of sucrose and
condensed milk. This difference between the two diets may thus account for the
dissimilar central locations of CB1 downregulation that were seen between the
two studies.
The sweetness of the diet used in Harrold et al.’s study may also account
for the disparate results seen for CB1 binding. Whilst CB1 antagonists reduce
responding for both sweet and fatty substances, research has shown that the
CB1 receptor deletion disrupts sweet food reinforcement but not fatty food
reinforcement (Ward and Dykstra, 2005). Furthermore, whilst both 1.0 and
3.0 mg/kg doses of

CB1 antagonist SR141716A decrease reinstatement of

Ensure® (sweet food) seeking in C57Bl/6 mice, a tenfold higher dose
(10.0 mg/kg) is required to attenuate reinstatement behaviour in C57Bl/6 mice
responding for corn oil (Ward et al., 2007). This suggests the CB1 receptor may
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be preferentially involved in the reinforcing effects of sweet as apposed to fatty
substances.
A total of seventeen brain regions were examined at two time points in
this study. Statistically, multiple comparisons without any correction of
significance level have the potential to increase the likelihood of a Type 1 error.
In order to control for a Type 1 error a Bonferroni adjustment was performed to
adjust the alpha level from 0.05 to 0.003 (i.e. 0.05/17, the number of tests
performed). This coupled with the fact that the specific brain sites that had
significant alterations are also related to feeding and reward reduces the
likelihood that these differences are due to a Type 1 error.
This study confirmed the involvement of the CB1 receptor in feeding
behaviour and high fat diet intake in a diet-induced obese mouse model.
Previous work has shown that high fat diet-induced obesity is characterised by
an early “defensive” stage at three weeks and a late defensive “failure” stage at
twenty weeks. The parallel increases seen in leptin and CB1 receptor binding at
week three support the likelihood that the peptidyl hormone may exhibit some
inhibitory control over endocannabinoid activity in the hypothalamus in the early
stages of obesity. As obesity progressed to the late stage a decrease in [3H]CP-55940 binding was seen in the substantia nigra and VTA. This is suggestive
of increased endocannabinoid activity in these reward-related areas which may
be a result of the chronic consumption of the palatable high fat diet and may in
turn help drive the hyperphagia that is characteristic of these late-stage obese
mice. Further pharmacological studies on CB1 receptors using this mouse
model may further clarify this receptor’s role in palatable feeding and reveal
promising new obesity treatments.
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Chapter 6. Temporal and Site-Specific Changes of Dopamine
D2 Receptor and Transporter in Fat-preferring Diet-Induced
Obese C57Bl/6 Mice

6.1 Introduction
One neurotransmitter that is known to be involved in the regulation of
palatable feeding via the mesolimbic (rewarding) circuit of the brain is dopamine
(Hajnal and Norgren, 2001, Hajnal et al., 2004). Consumption of palatable foods
and drugs of addiction activate dopamine releasing neurons that project from
the ventral tegmental area (VTA) to the nucleus accumbens and ventral
striatum (Spanagel and Weiss, 1999, Huang et al., 2006). The Dopamine D2
receptor plays a critical role in the regulation of dopaminergic function (Huang et
al., 2006). Conversely, D2 receptor densities can be regulated directly and
inversely by synaptic dopamine. Production of hyperdopaminergic mutant mice
has been shown to cause a downregulation of D2 mRNA levels in the striatum
(Fauchey et al., 2000).
Previous studies have revealed an inverse correlation between BMI and
striatal D2 binding in chronically obese humans and late stage diet-induced
obese C57BL/6 mice (Wang et al., 2001, Huang et al., 2006). However no
studies have examined D2 and DAT binding in the early stages of high fat dietinduced obesity. This experiment aims to examine the response of the
dopamine D2 receptor and dopamine transporter to three weeks of high fat
feeding as previous work has revealed that this time period corresponds to an
early defensive period of diet-induced obesity. Furthermore, upon the
completion of three weeks of high fat feeding, the high fat diet will be replaced
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with a low fat/carbohydrate diet for one and seven days to examine how the D2
receptor and DAT respond to acute alterations in macronutrient type and food
intake. The D2 receptor and DAT will not be examined following twenty weeks
like in other chapters as this has already been accomplished using this model
(Huang et al., 2006).

6.2 Materials and Methods
6.2.1 Dopamine D2 receptor autoradiography
Binding of [3H] Raclopride was used to assess binding density of the D2
receptor. The distribution of D2 receptor binding sites was determined from
Bregma 2.22mm to Bregma -3.28mm (Paxinos and Franklin, 2002). Sections
were allowed to defrost and then preincubated for one hour in Tris-HCl buffer
(50mM Tris-HCl, 120mM NaCl, 1nM MgCl2, pH 7.4) at room temperature. The
binding sites of D2 receptor were defined with 5nM [3H] Raclopride (76.8
Ci/mmol). Non-specific binding was determined in the presence of 10µM
Butaclamol. Following incubation for one hour at room temperature, slides were
washed for 2x5 minutes in ice cold Tris-HCl buffer. Then they were dipped
briefly in ice cold distilled water and dried under a gentle stream of cool air.
Slides were stored overnight in desiccators, and then apposed to Tritium
sensitive film for four weeks. Autoradiographs were developed using Kodak D19 developer and fixed with Ilford Hypam Rapid Fixer.

6.2.2 Dopamine Transporter binding autoradiography
Binding of [3H] WIN 35 428 (2β-carbomethoxy-3β - (4-fluorophenyl)-Nmethyl-3H tropane) was used to assess the binding density for DAT. The
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detection of DAT binding sites was carried out from Bregma 2.22mm to Bregma
-3.28mm (Paxinos and Franklin, 2002). Sections were first allowed to defrost
and then preincubated for 20 minutes in Tris-HCl buffer (50 mM Tris-HCl,
120mM NaCl, 0.1% bovine serum albumin, pH 7.4) at 4°C. The binding sites of
DAT were defined with 10nM [3H] WIN 35 428. Non-specific binding was
determined with 50µM Benztropine. Following incubation for 2 hours at 4°C,
slides were washed (2x1 minutes) in ice cold buffer, followed by one 30 second
dip in ice cold distilled water and dried under a stream of cool air. Slides were
stored overnight in desiccators, and then apposed for 3 weeks to [3H]-Hyperfilm
(Amersham) together with tritium standards for 3 weeks at 4°C. The films were
developed in Kodak LX 24 developer for 4 min.

6.2.3 Autoradiography Quantification
Autoradiographic images were captured and analysed using a computerassisted image analysis system, Multi-Analysis, connected to a GS-690 Imaging
Densitometer (Bio-Rad, USA). The density of binding was calculated by
converting the optical density of the image to nCi/gram with the aid of a
standard curve generated with calibrated [3H] microscales (Amersham, USA).
Individual brain nuclei were identified using a standard mouse brain atlas
(Paxinos and Franklin, 2002). The striatum was divided into rostral (bregma:
1.54 to 0.74mm), intermediate (bregma: 0.62 to -0.10mm) and caudal (bregma:
-0.10 to -0.82mm) according to a method used previously (Huang et al., 2005).
Furthermore, the sections of rostral and intermediate striatum were divided into
quadrants (dorsolateral, dorsomedial, ventrolateral and ventromedial) and the
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sections of the caudal part of the striatum were divided into two parts (dorsal
and ventral).

6.2.4 Statistical Analysis
Data from all experiments was analysed using the SPSS statistical
package (SPSS, Chicago, IL, USA). Comparisons between groups were
performed via one-way ANOVA and significant phenotype differences were then
ascertained with post-hoc Tukey-Kramer-HSD tests for multiple comparisons. .
As seventeen brain areas were examined at each time point, the chance of a
type-1 error was increased due to the large amount of tests. Therefore a
Bonferroni adjustment was performed to adjust the alpha level from 0.05 to
0.004 (0.05 divided by 13, the number of tests performed).

6.3 Results
One-way ANOVA revealed significant differences existed among the
groups for D2 binding in the dorsocaudal caudate putamen [F(3,22)=6.60,
p=0.003] and in the shell of the nucleus accumbens [F(3,22)=6.30, p=0.004]
(Fig. 6.2). One-way ANOVA also revealed significant differences among the
groups for DAT binding in the dorsomedial intermediate caudate putamen
[F(3,22)=7.24,

p=0.002],

[F(3,22]=6.26, p=0.004],

dorsolateral

intermediate

caudate

putamen

dorsocaudal caudate putamen [F(3,22)=7.19,

p=0.002] and the ventrocaudal caudate putamen [F(3, 22)=8.29, p=0.001]
(Fig 6.3).
After three weeks of feeding it was found that the D2 receptor levels of
the three week high fat fed mice were significantly greater than the three week
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low fat fed group in the dorsocaudal caudate putamen (32%) and in the shell of
the nucleus accumbens (36%) (Figs 6.1 and 6.2). Furthermore, the DAT binding
of the twenty-day high fat fed mice was found to be significantly lower than the
twenty-day low fat fed mice in the dorsocaudal caudate putamen (33.3%) and
ventrocaudal caudate putamen (28.8%) (Figs 6.1 and 6.3).
Replacement of the high fat diet with the low fat diet caused no
significant changes for D2 and DAT binding. However, the group fed a high fat
diet for three weeks and then switched to a low fat diet for one day was found to
have significantly higher D2 binding in the dorsocaudal caudate putamen (35%)
and in the shell of the nucleus accumbens (34%) (Fig 6.2). No differences in D2
binding were seen between the mice fed a high fat diet for three weeks and
switched to a low fat diet for seven days and the three week low fat fed group.
Following replacement of the high fat diet with the low fat diet it was also
found that the DAT binding was still significantly lower than the three week low
fat fed group after one (dorsomedial, 46.1%, dorsolateral, 32.0%, Fig 6.3) and
seven days (dorsomedial, 35.8%, dorsolateral, 33.8%) in the intermediate
caudate putamen. After high fat diet replacement, the groups fed a low fat diet
for one and seven days were also found to have significantly lower DAT in the
dorsocaudal caudate putamen (31.8% and 31.3% respectively), and in the
ventrocaudal caudate putamen (33.7% and 34.1% respectively)) compared to
the twenty-day low fat fed mice.
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Figure 6.1. Photographs depict the bindings of dopamine D2 receptor (B, C)
and dopamine transporter (D, E) in the brains of mice fed a high fat diet for
three weeks (B, D) or a low fat diet for three weeks (C, E). Abbreviations- AcbC,
nucleus accumbens core. AcbSh, nucleus accumbens shell. CPu, Caudate
Putamen. Tu, Olfactory tubercle. DL, dorsolateral. DM, dorsomedial. VL,
ventrolateral. VM, ventromedial.
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Figure 6.2. Specific [3H] Raclopride binding in the mouse brain following three
weeks high fat feeding (3WK HF), three weeks low fat feeding (3WK LF), or
three weeks of high fat feeding followed by one (3WK HF+LF1) or seven days
(3WK HF+LF7) of low fat. * p<0.05 vs. 3WK LF.
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Figure 6.3. Specific [3H] WIN 35 428 binding in the mouse brain following three
weeks high fat feeding (3WK HF), three weeks low fat feeding (3WK LF), or
three weeks of high fat feeding followed by one (3WK HF+LF1) or seven days
(3WK HF+LF7) of low fat feeding. * p<0.05 vs. 3WK LF.
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Analysis of dopamine D2 receptor binding revealed a positive correlation
between binding in the caudal caudate putamen and shell of the nucleus
accumbens with final bodyweight (Table 6.1). Furthermore, a positive
correlation was found for D2 receptor binding in the shell of the nucleus
accumbens and plasma leptin. A negative correlation was found between DAT
and leptin and final body weight in the shell of the nucleus accumbens, and both
the caudal and the intermediate caudate putamen.

Table 6.1. Relationship of D2 and DAT binding to final body weight and leptin
D2 Receptor Binding
DAT Receptor Binding
Intermediate CPu FBW
leptin
FBW
leptin
DM 0.0259 (0.91)
0.271 (0.22)
-0.750 (0.005)* -0.604 (0.002)*
DL 0.0535
0.335 (0.13)
-0.654 (0.001)* -0.699 (0.001)*
VM 0.009
0.236 (0.29)
-0.648 (0.001)* -0.531 (0.001)*
VL 0.064
0.245 (0.27)
-0.667 (0.001)* -0.455 (0.03)*
Caudal CPu
D
0.492 (0.02)*
0.166 (0.45)
-0.587 (0.003)* -0.587 (0.003)*
V
0.469 (0.02)*
0.087 (0.69)
-0.614 (0.002)* -0.719 (0.0001)*
AcbSh
0.692 (0.0003)* 0.546 (0.007)* -0.638 (0.001)* -0.665 (0.0004)*
Data in parentheses represents p value. * p < 0.05. FBW; final body weight

6.4 Discussion
This experiment examined D2 receptor and DAT densities in C57BL/6
mice that were fed either a high fat diet for three weeks, a low fat diet for three
weeks, or fed a high fat diet for three weeks and then changed to the low fat
diet for one or seven days. The main findings were: (1) high fat diet
consumption for three weeks significantly increased D2 receptor, but decreased
DAT binding density in the caudal caudate putamen; (2) replacement of the high
fat diet with a low fat diet caused no significant differences in D2 and DAT
binding; and (3) final body weight was found to be positively correlated with D2
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receptor but negatively correlated with DAT binding in the caudal caudate
putamen and nucleus accumbens shell.
This study found that mice that are fed a high fat diet for three weeks
have increased D2 receptor binding in the caudal caudate putamen and the
shell of the nucleus accumbens compared to mice fed a low fat diet for a similar
time period. These regions of the brain have been implicated in reward and
motivation (Kelley et al., 2005). As well as having higher D2 binding levels, the
mice fed a high fat diet for three weeks also had lower DAT binding levels in the
caudal caudate putamen compared to the mice fed a low fat diet for the same
time period. Previous studies have shown an inverse relationship exists
between synaptic dopamine and D2 levels, whilst a positive relationship exists
between DAT and synaptic dopamine (Ikawa et al., 1993, Fauchey et al., 2000).
Thus, the combination of higher levels of D2 and low levels of DAT binding seen
in the caudal caudate putamen and nucleus accumbens shell of the mice fed a
twenty-day high fat diet suggest they may have had lower striatal dopaminergic
activity compared to the chronically low fat fed group. This lower dopaminergic
activity may have caused a compensatory decrease and increase of DAT and
D2 levels respectively in order to drive synaptic dopamine back to homeostatic
levels.
Following the replacement of the high fat diet with the low fat diet, no
significant changes for the D2 receptor and dopamine transporter were detected
between groups despite any differences in food palatability, energy intake and
macronutrient content of the two diets. Acute increases in both food intake and
palatability (both sucrose and fat) have been shown to stimulate dopamine
release in the striatum and nucleus accumbens (Martel and Fantino, 1996,
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Epstein and Leddy, 2006, Liang et al., 2006). However it is possible that this
acute release of dopamine may have become diminished following the
prolonged consumption of the palatable high fat diet. This may in turn explain
why an initial high fat hyperphagia seen in week 1 subsided by week 3 in the
twenty-day high fat fed mice. The fact that the D2 receptor binding remained
high and DAT binding remained low following diet replacement suggest that
dopamine and its receptors may be influenced by alterations in prolonged high
fat feeding.
As well as having higher D2 receptor binding levels, the three week high
fat fed and 3wk HF+1day LF mice were found to have an elevated final body
weight compared to the three week low fat fed mice (Table 4.1). Indeed positive
correlations were found between final body weight and D2 binding in the shell of
the nucleus accumbens and the caudal caudate putamen. Also, a negative
relationship was found between DAT and final body weight in the intermediate
caudate putamen, caudal caudate putamen and the shell of the nucleus
accumbens. This suggests dopaminergic activity may be under regulatory
control in relation to changes body weight and chronic energy balance.
As mentioned previously, the three week low fat fed group had
significantly lower plasma leptin levels than the groups fed a high fat diet for
three weeks and then switched to the low fat diet. Studies have revealed that
tyrosine hydroxylase is co-expressed with leptin receptors in areas that project
to the striatum (i.e. ventral tegmental area and substantia nigra) (Figlewicz,
2003, Figlewicz et al., 2003). Further studies have revealed that leptin acts
directly on dopaminergic neurons in the VTA and reduces their firing (Hommel
et al., 2006). This in turn leads to a reduction of dopamine release in the
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nucleus accumbens (Krugel et al., 2003). In this study, a positive correlation
was found between dopamine D2 receptor levels and plasma leptin in the shell
of the nucleus accumbens. Furthermore, a negative correlation was also found
between DAT and leptin in the shell of the nucleus accumbens, and the caudal
caudate putamen. Thus the higher leptin levels seen in the high fat fed mice
may have inhibited dopamine release in the striatum and nucleus accumbens.
This may have led to compensatory upregulation of the D2 receptor and a
downregulation of DAT and may thus explain the alterations in their levels.
Whilst this experiment has revealed a positive correlation between final
body weight and striatal D2 receptor levels, other studies have reported the
reverse situation in humans and rodents. A study by Wang et al. has found BMI
is inversely related to striatal dopamine D2 receptor levels in obese individuals
(Wang et al., 2001). It should be noted however that the subjects in their study
were severely obese (i.e. BMI > 40kg/m2). C57BL/6 mice that have been made
severely obese through twenty weeks of high fat feeding also have decreased
D2 levels in the striatum (Huang et al., 2006). Severe obesity has been
associated with both leptin and insulin insensitivity in both rodents and humans
(Maffei et al., 1995, Kolaczynski et al., 1996, Lin et al., 2000, Scarpace and
Tumer, 2001).

Thus a chronically elevated food intake coupled with

insulin/leptin insensitivity in severely obese individuals may lead to unabated
striatal dopaminergic activity which would in turn cause a compensatory
downregulation of the D2 receptor. Previous studies have shown C57BL/6 mice
in the early stages of obesity are still leptin sensitive and thus this
compensatory downregulation would not have occurred in the present study.
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The present study in conjunction with previous work has revealed that
striatal D2 receptor levels are differentially regulated in the early and late stages
of diet-induced obesity in C57Bl/6 mice (Huang et al., 2006). Interestingly, it has
been revealed that

lean and overweight individuals have increased reward

sensitivity whilst morbidly obese individuals have decreased reward sensitivity
(Davis and Fox, 2008). It is possible that these differences in reward sensitivity
may correlate with the increased and decreased striatal D2 receptor levels seen
in the early and late stages of obesity respectively. Future studies that examine
the relationship between reward sensitivity and striatal D2 receptor levels in preobese and obese humans may confirm whether this is the case.
In summary, this study has provided new information on the involvement
of the dopamine transporter and D2 receptors in high fat diet consumption and
early-stage obesity development. This experiment has revealed that mice that
consumed diets higher in fat had elevated D2 levels and decreased DAT levels
in the nucleus accumbens shell and the caudal caudate putamen. These altered
levels may reflect a compensatory increase and decrease respectively in
receptor levels due to an inhibition of synaptic dopamine release. This inhibition
of dopamine release may have resulted from an increase in anorectic hormones
such as insulin and leptin following chronic high fat diet consumption, and thus
may represent

an attempted

defensive

development.
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response

to

prevent

obesity

Chapter 7: Temporal and Site-Specific Alterations in Opioid Mu
Receptor Binding in Fat-preferring Diet-Induced Obese C57Bl/6
Mice

7.1 Introduction
A receptor that has been implicated in the control of palatable feeding is
the opioid mu receptor. Opioid mu receptors are G-coupled protein receptors
that are widely expressed in several areas of the brain including the striatum,
amygdala, and thalamus (Mansour et al., 1987). They are acted upon by a
variety of endogenous opioid ligands such as β-Endorphin, Met-enkephalin and
Lue-enkephalin (Hadcock and Scott, 2005). Pharmacological stimulation of
opioid mu receptors by morphine has been shown to preferentially increase the
consumption of palatable diets (Gosnell et al., 1990, Levine et al., 1995), whilst
mu inhibition with the antagonist naloxone causes the reverse effect (Apfelbaum
and Mandenoff, 1981). Also, mutant mice lacking either β-endorphin or
enkephalin have a reduced responding for palatable food reinforcers (Hayward
et al., 2002). Furthermore, the chronic consumption of palatable foods has been
shown to cause an increase in hypothalamic mu opioid receptors and reduced
striatal enkephalin levels (Kelley et al., 2003).
The implication of the opioid mu receptors involvement in palatable
feeding makes it an appealing candidate for investigations of diet-induced
obesity. For this reason, this study aimed to use the previously established fatpreferring obese-prone mouse model to examine the involvement of the opioid
mu receptor in obesity. The opioid mu receptor was examined at both the early
and late stages of obesity to see how it is affected through the course of the
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disease. Furthermore, the opioid mu receptor was also examined in the early
obese mice following replacement of the high fat diet with a low fat diet for one
and seven days. This was done to examine how the receptor responds to acute
as apposed to chronic alterations in food intake and diet type. It is hypothesized
that information gained from this study will demonstrate that the opioid mu
receptor is an important candidate involved in macronutrient preference, energy
intake and obesity.

7.2 Materials and Methods
7.2.1 Opioid mu receptor autoradiography
Binding density of the opioid mu receptor was defined with [3H] DAMGO
(D-Ala2-NMePhe4-Gly-ol-enkephalin) using a protocol previously described
(Mansour et al., 1987). The distribution of opioid mu binding sites was
determined from Bregma 2.22mm to Bregma -2.70mm (Paxinos and Franklin,
2002). Sections were allowed to defrost and then preincubated for thirty minutes
in Tris-HCl buffer (50mM Tris-HCl, 120mM NaCl, 1nM MgCl2, pH 7.4) at room
temperature. The binding sites of opioid mu receptor were defined with 2.7nM
[3H] DAMGO (37.2 Ci/mmol). Non-specific binding was determined in the
presence of 1µM Naloxone. Following incubation for one hour at room
temperature, slides were washed for 2x6 minutes in ice cold Tris-HCl buffer.
Then they were dipped briefly in ice cold distilled water and dried under a gentle
stream of cool air. Slides were stored overnight in desiccators, and then placed
in a beta imager for three and a half hours.
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7.2.2 Beta imager Quantification
Autoradiographic images for opioid mu receptor binding were taken using
a beta image camera (Biospace, Paris). All sections were scanned for 3.5 hours
at high resolution. A series of sections with a known amount of ligands was
used as standards in all scans. The measurement of radioligand binding signals
is in nCi/mg tissue. Quantitative analysis of these images was performed with
the program β-Image Plus (version 4, Biospace). A set of sections was stained
with Cresyl Violet for confirmation of anatomical structures (Paxinos and
Franklin, 2002). Receptor densities were determined by calculating the average
of three adjacent brain sections, including left and right hemispheres. Specific
binding was calculated by subtraction of non-specific binding from total binding.

7.2.3 Statistical Analysis
Comparisons between groups were performed via one-way ANOVA and
significant phenotype differences were then ascertained with post-hoc TukeyKramer-HSD tests for all comparisons. Data are expressed as means ± S.E.M.
As five brain areas were examined at each time point, the chance of a type-1
error was increased due to the amount of tests. Therefore a Bonferroni
adjustment was performed to adjust the alpha level from 0.05 to 0.01 (0.05
divided by 5, the number of tests performed).

7.3 Results
Autoradiography revealed that opioid mu binding sites were distributed
throughout the brain in areas such as the nucleus accumbens, thalamus and
amygdala, posteromedial cortical amygdaloid nucleus and the retrosplenial
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cortex. One-way ANOVA revealed that [3H] DAMGO binding in the groups fed
for three weeks was significantly different in the nucleus accumbens
[F(3,23)=8.28, p=0.001] and amygdala [F(3,23)=6.22, p=0.004], but not the
posteromedial cortical amygdaloid nucleus [F(3,23)=2.23, p=0.12], retrosplenial
cortex [F(3,23)=1.07, p=0.38] or the anterior paraventricular thalamic nucleus
[F(3,23)=1.39, p=0.28].
Further post hoc analysis revealed there were no significant differences
in the nucleus accumbens for the mice fed a high fat diet or a low fat diet for
three weeks. However, switching from a high fat diet after three weeks to a low
fat diet for one day caused a significant increase in [3H] DAMGO binding in only
the nucleus accumbens compared the 3 week high fat and low fat groups (17%
vs. 3wk HF & 18% vs. 3wk LF). Furthermore, switching from a high fat diet after
three weeks to a low fat diet for seven days caused a significant increase in [3H]
DAMGO binding in the nucleus accumbens compared to the mice fed a high fat
diet or a low fat diet for three weeks (19% vs. 3wk HF & 22% vs. 3wk LF).
Switching from a high fat diet after three weeks to a low fat diet for seven days
also caused a significant increase in [3H] DAMGO binding in the amygdala
compared to the three week high fat and low fat fed groups (17% vs. 3wk HF &
16% vs. 3wk LF; Fig 7.1).
Following twenty weeks of feeding it was found that [3H] DAMGO binding
was not significantly different from the low fat fed controls in the nucleus
accumbens

[F(1,8)=0.91,

p=0.37],

amygdala

[F(1,9)=0.63,

posteromedial cortical amygdaloid nucleus [F(1,8)=0.33, p=0.58],
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p=0.45]

,
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Figure 7.1 Specific [3H] DAMGO binding in the brains of C57Bl/6 mice fed a
high fat diet for three weeks (black bars), a low fat diet for three weeks (white
bars), or a high fat diet for three weeks followed by a low fat diet for one (gray
bars) and seven days (diagonally striped bars). Data are expressed as means ±
S.E.M. of nCi/g, *: P < 0.05 versus 3wk HF and 3wkLF. Abbreviations: ACB,
nucleus accumbens, RS, retrosplenial cortex. PVA, anterior paraventricular
thalamic nucleus. AMG, amygdala. PMCO, posteromedial cortical amygdaloid
nucleus.
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Figure 7.2 Specific [3H] DAMGO binding in the brains of C57Bl/6 mice fed a
high fat diet for twenty weeks (black bars) or a low fat diet for twenty weeks
(white bars). Data are expressed as means ± S.E.M. of nCi/g. Abbreviations:
ACB, nucleus accumbens. RS, retrosplenial cortex. PVA, anterior
paraventricular thalamic nucleus. AMG, amygdala. PMCO, posteromedial
cortical amygdaloid nucleus.
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anterior paraventricular thalamic nucleus [F(1,9)=0.63, p=0.45] or the
retrosplenial cortex [F(1,9)=0.03, p=0.86] (Fig 7.2).

7.4 Discussion
This experiment examined the involvement of the opioid mu receptor in a
fat-preferring obese-prone strain of mouse. When C57Bl/6 mice were fed a high
fat diet for three weeks, no significant differences were found in [3H] DAMGO
binding compared to the low fat fed controls. Replacement of the high fat diet
after three weeks of feeding with the low fat diet for one and seven days caused
an increase in opioid mu binding in the nucleus accumbens and an increase in
the amygdala after seven days in the C57Bl/6 mice. Obese C57Bl/6 mice that
were fed a high fat diet for twenty weeks were found to have no significant
differences in [3H] DAMGO binding in all areas of the brain examined compared
to the lean low fat fed controls.
Results from this experiment revealed that [3H] DAMGO binding was
increased in the nucleus accumbens following replacement of the high fat diet
with the low fat diet for one and seven days and increased in the amygdala after
seven days. Notably, this increase in opioid mu receptor binding occurred in
conjunction with a drop in energy intake that remained significantly lower than
the three week high fat and low fat fed groups throughout the seven day diet
reversal (Table 4.1). Thus it is possible that these acute changes in energy
intake or macronutrient type may account for the differences seen in [3H]
DAMGO binding. This suggests that the opioid mu receptor is affected by acute
changes in energy intake and macronutrient consumption.

Page 128

The opioid mu receptor, like other G-protein coupled receptors has been
shown to have an inverse relationship with its endogenous ligands (Zukin and
Tempel, 1986). Enkephalin knockout mice have markedly increased levels of
opioid mu receptor binding in the limbic forebrain (Brady et al., 1999). Also,
transgenic mice that have elevated central enkephalin levels exhibit a 21%
decrease in opioid mu receptor density (Fischer et al., 2000). Thus the increase
in opioid mu receptor binding that occurred following one and seven days of
high fat diet reversal may reflect a decrease in endogenous opioid ligand
release in the nucleus accumbens and amygdala. However future studies will
have to directly measure levels of endogenous opioid ligands in this model to
confirm whether this is the case.
Research on β-endorphin, a major ligand for the opioid mu receptor, has
revealed that the consumption of a palatable diet increases and food
deprivation decreases its expression (Dum et al., 1984, Aravich et al., 1993,
Kim et al., 1996, Welch et al., 1996). Also, consumption of palatable sucrose
and saccharin solutions cause an increase in β-endorphin in the cerebrospinal
fluid of Wister rats (Yamamoto et al., 2000). Conversely, periods of increased
food intake have been characterised by significant elevations in plasma βendorphin (Davis et al., 1983). This implies that the reductions in energy intake
and diet palatability that occurred following diet reversal may have decreased βendorphin levels and subsequently caused an increase in opioid mu receptor
binding density. Future studies that examine β-endorphin protein expression in
this model will confirm whether this is the case.
The increase in opioid mu receptor binding that occurred following diet
reversal may be explained by alterations in another endogenous mu ligand;
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enkephalin. Studies have revealed that acute food deprivation raises striatal
preproenkephalin mRNA (the precursor for the endogenous ligands of the mu
and delta opioid receptors) levels regardless of whether or not an animal has
undergone long term energy restriction (Will et al., 2007). Kelly et al. have also
shown that scheduled consumption of a palatable, energy dense, chocolate
Ensure® (Abbott Nutrition, Columbus, OH, USA) diet by rats causes a decrease
in preproenkephalin mRNA expression in the ventral striatum and nucleus
accumbens (Kelley et al., 2000). The researchers of these studies suggest the
increases and decreases in preproenkephalin mRNA occur as compensation to
decreased and increased levels of striatal enkephalin respectively (Kelley et al.,
2003, Will et al., 2007). These findings suggest that striatal endogenous
enkephalin activity may be positively related to increases in short term energy
intake and palatability. Thus, the decrease in energy intake following the diet
reversal in the current study may have caused a decrease in enkephalin release
in the nucleus accumbens. This in turn may have lead to a compensatory
upregulation of opioid mu receptor levels and thus may account for the increase
levels of [3H] DAMGO binding that were observed.
Despite any differences in energy balance or macronutrient type, no
significant differences in [3H] DAMGO binding were detected throughout the
brains of the three week and twenty week high fat and low fat diet fed groups.
This is surprising when the wealth of data linking the opioid mu receptor to
palatable feeding and obesity is considered (Zhang and Kelley, 2000, Smith et
al., 2002, Will et al., 2003). It is possible that differences in palatability may not
have been sufficient in the current experiment to affect opioid receptor binding.
Also, the prolonged consumption of the high fat diet in the current study may
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have reduced the perceived palatability of the food thus reducing its effect on
the opioid system. Other differences in animal species and strain, diet
macronutrient composition and energy balance status may also account for
differences between the current results and those in the literature.
Late stage high fat diet-induced obese mice were found to have similar
[3H] DAMGO binding levels as the lean low fat fed controls throughout the brain.
This implies that long term alterations in energy balance have no effect on
opioid mu receptor binding. Replacement of the high fat diet with the low fat diet
for one and seven days did however affect [3H] DAMGO binding in the nucleus
accumbens. This finding suggests acute alterations in macronutrient type and
energy intake affect the opioid mu receptor rather than long term alterations in
energy balance. Interestingly, a study by Will et al. has found that
preproenkephalin mRNA expression is downregulated in the striatum of rats
that have recently consumed a meal of lab chow but is unaffected by
differences in long term energy balance (Will et al., 2007). This finding suggests
that striatal enkephalin may have a role in short-term rather than long-term food
consumption which may in-part explain the results seen for opioid mu receptor
binding in the current study.
Whilst previous studies have found differences in energy balance affect
the opioid mu receptor, it should be noted there is great disparity among the
results in the literature. Some studies have revealed that chronic obesity leads
to an increased opioid mu receptor density in the brain (Smith et al., 2002,
Barnes et al., 2003). However, others have shown obesity in both humans and
mice has the opposite effect on the opioid mu receptor causing it to be
decreased centrally in both humans and rodents (Roane et al., 1988, Khawaja
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et al., 1989, Rota et al., 2008). The present study has shown that the opioid mu
receptor binding may be affected by differences in short-term feeding and
macronutrient type rather than chronic energy balance. Thus it is possible that
differences in short-term energy intake and diet type may account for the
disparate results found in the literature.
Both the nucleus accumbens and the amygdala experienced changes in
[3H] DAMGO binding in this study. Whilst the relationship of the nucleus
accumbens with opioid-induced feeding is well-established it is not as clear in
the amygdala. One study has revealed that infusion of the opioid mu antagonist
naltrexone into the amygdala decreases the intake of a rat’s preferred diet with
no change in its non-preferred diet (Glass et al., 2000). Another study has
shown that inactivation of the amygdala can inhibit an increased fat intake that
is induced by administration of the mu agonist DAMGO to the nucleus
accumbens (Will et al., 2004). This implies important circuitry exists between
the amygdala and nucleus accumbens for the opioid-related regulation of high
fat feeding. This may in turn explain why alterations in [3H] DAMGO binding only
occurred in these two areas following high fat diet replacement.
It should be noted that the ligand used in this experiment ([3H] DAMGO)
is an agonist and thus the alterations seen in binding density in this experiment
may be representative of either receptor density or receptor function. As a
result, future studies should also examine agonist stimulated [35S] GTPγS
binding to determine if any alterations in opioid mu receptor function have also
occurred. Also, quantification of µ-opioid receptors via immunohistochemical
approaches will help clarify whether changes in binding reflect changes in
protein level. Nevertheless, chronic administration of both exogenous and
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endogenous opioid mu receptor agonists is associated with compensatory
decreases in both opioid mu receptor density and sensitivity in vitro (Yabaluri
and Medzihradsky, 1997, Harrison et al., 2000). Thus, the increases seen in
[3H] DAMGO binding in the current project may still reflect a decrease in
endogenous ligand levels regardless of whether it is indicative of increased
receptor density or function. However future studies will have to directly
measure levels of endogenous opioids in this model to confirm if this is the
case.
In conclusion, this study has confirmed the opioid mu receptor’s
involvement in energy intake and palatable feeding. Long term differences in
energy balance and obesity level had no effect on opioid mu receptor binding in
the brains of the C57Bl/6 mice. Conversely, the reversal of a high fat to a low fat
diet for one and seven days caused a significant increase in opioid mu receptor
binding in reward and feeding related areas. This raises the possibility that the
opioid mu receptor is affected by alterations in short term energy intake and
macronutrient type rather than long term energy balance.
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CHAPTER 8: Summary and Conclusions
8.1 Summary
This thesis has highlighted an important link between high fat diet
consumption, obesity development and palatable feeding-related receptors. It
was found that obese-prone C57Bl/6 mice prefer to consume a high fat diet
over a low fat diet. Furthermore it was found that the palatable feeding–related
CB1, opioid mu and dopamine D2 receptors are not only able to modulate the
energy intake and fat preference of these mice but may also be involved in their
development of obesity.
In the first study it was found that C57Bl/6 mice are not only prone to
obesity development but also have a high preferential consumption of dietary
fat. Of all the strains examined, C57Bl/6 mice were the strongest fat preferrers
consuming 72% of their calories from the high-fat diet, whereas the BALB/c
mice were found to have no macronutrient preference. The C57Bl/6 mice were
also found to be the most obesogenic of the inbred strains having the highest
BWG/IBW and energy efficiency for the thirty days. The reliable weight gain that
these mice produce on a high-fat diet, coupled with their high-fat preference,
makes the C57Bl/6 strain an excellent candidate for use in an animal model that
examines fat preference and its relationship with obesity.
A relationship between preferential dietary fat consumption and palatable
feeding-related receptors was established in the second study. Fat-preferring
C57Bl/6 mice that were treated with the CB1 inverse agonist AM 251, the opioid
mu antagonist β-Funaltrexamine and the D2 receptor agonist Bromocriptine
similarly reduced their total energy intake via a specific reduction of high fat diet
energy intake. Whilst Bromocriptine did not affect fat preference both AM 251
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and β-Funaltrexamine did. However, future studies that alter the treatment
period, dosage rate and baseline macronutrient preference of the mice will
provide a clearer understanding of the effects of all three drugs.
Finally a relationship between obesity development and the central
expression of palatable feeding-related receptors was established in the third
study. In this experiment, the levels of CB1 receptor, opioid mu receptor,
dopamine D2 receptor and dopamine transporter binding were examined in
C57BL/6 mice in the early and late stages of obesity. It was hoped that
examining these receptors at three and twenty weeks of high fat feeding would
give an insight into their relationship to the early “defensive” and late defensive
“failure” stages of obesity in the C57Bl/6 mice.
In the early stage of obesity it was found that CB1 and D2 receptor
binding was increased in central areas related to palatable feeding whilst opioid
mu receptor levels remained unchanged. CB1 receptor binding levels were
increased in the nucleus accumbens, anterior olfactory nucleus and agranular
insular cortex whilst the D2 receptor binding levels were increased in the
nucleus accumbens shell and caudate putamen. The increase in D2 receptor
binding seen in the striatum was accompanied by a decrease in dopamine
transporter levels raising the possibility that dopamine levels may be decreased
in the early stages of obesity.
In the late stages of obesity a decrease in CB1 receptor binding was
found in the substantia nigra and ventral tegmental area. Like the CB1 receptor,
previous work using the twenty week C57Bl/6 mice has also revealed a
decrease in D2 receptor binding levels in the late stage of obesity (Huang et al.,
2006). Conversely, twenty weeks of high fat feeding was found to have no
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effects on opioid mu receptor binding levels in the brains of the C57Bl/6 mice.
These findings suggest that unlike the D2 and CB1 receptors, long term
differences in energy balance and obesity level have no effect on opioid mu
receptor binding in the brains of the C57Bl/6 mice.
In the final study, mice were also fed a high fat diet for three weeks which
was replaced with a low fat diet for one and seven days so as to gain an insight
into how these receptors are influenced by acute alterations in macronutrient
type and energy intake. Replacement of the high fat diet with the low fat diet for
one and seven days was found to have no effects on CB1 receptor, D2 receptor
and DAT binding levels. In contrast opioid mu receptor binding was found to be
increased in the nucleus accumbens and amygdala following replacement of
the high fat diet with the low fat diet for one and seven days. This raises the
possibility that unlike the CB1 and dopamine D2 receptors, the opioid mu
receptor is influenced by alterations in short term energy intake and
macronutrient type rather than long term energy balance.

8.2 Suggestions for Future Research
Based on the findings in the present thesis, recommendations for future
research are listed below.
1)

Whilst the current project used ligand binding autoradiography to
demonstrate a relationship between obesity and the CB1, opioid mu
and dopamine D2 receptors, this technique is not without limitations.
Alterations in receptor binding can be indicative of changes in receptor
density, receptor function or both. Therefore future studies should
examine

these

receptors

in

this
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obesity

model

by

using

immunohistological and in situ hybridisation techniques to confirm
whether these receptor changes occur at both the level of protein and
gene expression. Furthermore, future studies should also examine
agonist stimulated [35S] GTPγS binding to determine if any alterations in
receptor function have also occurred.
2)

It is possible that alterations in receptor binding seen in the current
study may be indicative of alterations in endogenous ligand levels.
However, this cannot be confirmed without further study. Future studies
should examine how the levels of dopamine and endogenous
cannabinoids and opioids are altered throughout obesity development
to gain a greater insight into their relationship with energy balance.

3)

Whilst the current project focused on the obese-prone C57Bl/6 mice,
future studies may examine the macronutrient non-preferring BALB/c
mice. Examining how the opioid mu, CB1 and D2 receptors respond to
both pharmacological manipulation and high fat diet consumption in
these mice will provide a greater insight into how they are related to
macronutrient preference and the development of obesity.

4)

This project revealed that drugs that act on the opioid mu, dopamine D2
and cannabinoid CB1 receptors can alter energy intake and
macronutrient preference in C57Bl/6 mice. However, given the broad
distribution of these receptors throughout the brain, the other
physiological and psychological aspects of these drug treatments also
need to be assessed. A more effective future means of acting on these
receptors may be to treat them simultaneously. The resulting synergistic
effects of this combined treatment on energy intake would allow the use
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of lower dosages which would in turn decrease the potential for
negative side effects.

8.3 Final Conclusions
In conclusion, this project established a novel murine model that allows
the analysis of the central mechanisms related to macronutrient preference and
obesity

development.

In

addition,

it

revealed

that

pharmacological

manipulations of the CB1 receptor, opioid mu receptor and dopamine D2
receptor can alter the macronutrient consumption and energy intake of C57Bl/6
mice. Whilst all receptors were shown to affect feeding, the final study revealed
they differ in their relationship to energy balance regulation. The opioid mu
receptor was shown to be influenced by acute changes in energy intake and
macronutrient type, whilst the CB1 and D2 receptors were shown to be altered
by long term alterations in energy balance. The CB1 and D2 receptors were
shown to be upregulated in the early stages of obesity and decreased in the late
stage of obesity. These changes may be indicative of defensive regulation of
the CB1 and D2 receptor that is initially intact in the early stages of obesity but
fails as obesity progresses. The loss of regulation of these receptors in the late
stage of obesity may be one contributing factor to the hyperphagia and
accelerated weight gain that is characteristic of morbidly obese individuals.
As rates of obesity climb higher on a global scale it is of paramount
importance that effective treatments are developed that can prevent the growing
epidemic. The current project has shown that the opioid mu receptor,
cannabinoid CB1 receptor, and dopamine D2 receptor are highly involved in the
regulation of feeding, macronutrient preference and energy balance. These
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results have significant practical implications as they provide potential targets
for the future treatment of obesity. The development of pharmacological
treatments that reduce both appetitive and palatable feeding by specifically
targeting these receptors may be a critical future step in combating the rising
rates of obesity in Australia and around the world.
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